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Summary 
 
Type 2 diabetes is a metabolic disorder with globally increasing prevalence. Therefore, the 
identification of etiological factors is of ascending relevance for the understanding, treatment, and 
prevention of the disease. Levels of the acute-phase serum amyloid A (A-SAA) protein have been 
found to be elevated in type 2 diabetic subjects, but little is known about their causal implication in 
the development of type 2 diabetes so far. This doctoral thesis presents an epidemiological perspective 
on the association between circulating levels of A-SAA and risk of type 2 diabetes and assesses a 
possible causality in this association using a genetic approach.  
Three studies were conducted. In a prospective cohort study, A-SAA levels were measured in 836 
initially non-diabetic, elderly, Western European subjects without clinically overt inflammation who 
participated in a seven-year follow-up examination. Results of this study provided first evidence that 
levels of A-SAA are elevated years before the manifestation of type 2 diabetes independent of other 
type 2 diabetes risk factors. However, adjustment for parameters related to glucose metabolism, 
particularly levels of 2h-glucose, attenuated the association suggesting a potential link via post-
challenge hyperglycemia in the association between elevated levels of A-SAA and type 2 diabetes or, 
alternatively, a possible reverse causality between levels of A-SAA and 2h-glucose. In a meta-
analysis of genome-wide association studies (GWAS) on levels of A-SAA conducted in three 
population-based studies and one prospective case-cohort study including a total of 4,212 participants 
of European descent two biologically highly plausible genetic susceptibility loci for A-SAA proteins 
at chromosome 11p15.5-p13 and chromosome 1p31 were identified. One of these loci represented a 
suitable candidate for a Mendelian Randomization study. In Mendelian Randomization studies, 
genetic variants are used as proxies for a biomarker. These studies benefit from the fact that genotypes 
are randomly assorted at meiosis and are largely independent of non-genetic confounding and disease 
processes. Thus, they constitute a genetic approach to assess whether the association between a 
biomarker and a disease is causal. The associations between genetic variants of the candidate locus 
and type 2 diabetes were extracted from the results of a meta-analysis of eight GWAS (8,130 cases, 
38,987 controls) published by DIAGRAM, a large diabetes and genetic consortium. In spite of 
sufficient power, the above mentioned associations were not significant suggesting that there are 
genetic mechanisms that raise plasma levels of A-SAA without translating into an increase in type 2 
diabetes risk.  
In conclusion, results of this doctoral thesis indicated that levels of A-SAA are elevated years before 
the manifestation of type 2 diabetes but could not provide evidence that the association is truly causal 
using a genetic approach. Rather it seems likely that the association between levels of A-SAA and risk 
of type 2 diabetes is substantially influenced by post-challenge hyperglycemia. Time-series studies are 
warranted to elucidate the role of post-challenge hyperglycemia in this association. 
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Zusammenfassung 
Typ 2 Diabetes ist eine Stoffwechselerkrankung mit weltweit zunehmender Prävalenz. Daher ist die 
Identifizierung ätiologischer Faktoren für Verständnis, Behandlung und Prävention der Erkrankung 
von steigender Bedeutung. In Typ 2 Diabetikern wurden erhöhte Spiegel des Akut-phase Serum 
Amyloid A (A-SAA) Proteins festgestellt, bisher ist allerdings wenig über ihre kausale Mitwirkung an 
der Entstehung von Typ 2 Diabetes bekannt. Diese Dissertation bietet eine epidemiologische Sicht auf 
den Zusammenhang zwischen zirkulierenden A-SAA Spiegeln und das Typ 2 Diabetesrisiko und 
untersucht mithilfe eines genetischen Ansatzes eine mögliche Kausalität dieses Zusammenhangs. 
Drei Studien wurden durchgeführt. In einer prospektiven Kohortenstudie wurden A-SAA Spiegel in 
836 anfangs nicht-diabetischen, älteren, westeuropäischen Probanden ohne klinisch offenkundige 
Inflammation, die an einer sieben Jahre späteren Anschlussuntersuchung teilnahmen, gemessen.  
Ergebnisse dieser Studie gaben erste Hinweise darauf, dass A-SAA Spiegel unabhängig von anderen 
Typ 2 Diabetes Risikofaktoren vor der Manifestation von Typ 2 Diabetes erhöht sind. Eine 
Adjustierung für Parameter des Glukosestoffwechsels, insbesondere für 2h-Glukose Spiegel, 
schwächten jedoch den Zusammenhang ab, was auf einen potentiellen Link zwischen erhöhten A-
SAA Spiegeln und Typ 2 Diabetes über post-challenge Hyperglykämie oder, alternativ, eine mögliche 
umgekehrte Kausalität zwischen A-SAA-und 2h-Glukose Spiegeln hindeutet. In einer Metaanalyse 
genomweiter Assoziationsstudien (GWAS) zu A-SAA Spiegeln, die in drei populationsbasierten 
und einer prospektiven Fall-Kontroll-Studie mit insgesamt 4,212 Teilnehmern europäischer Herkunft 
durchgeführt wurde, wurden zwei biologisch sehr plausible A-SAA Prädispositionsorte auf 
Chromosom 11p15.5-p13 und Chromosom 1p31 gefunden. Einer davon stellte einen geeigneten 
Kandidaten für eine Mendelsche Randomisierungsstudie dar. In Mendelschen Randomisierungs-
studien werden genetische Varianten stellvertretend für Biomarker untersucht und die Tatsache 
genutzt, dass Genotypen in der Meiose zufällig vererbt werden und weitgehend unabhängig von nicht-
genetischen Störfaktoren und Krankheitsprozessen sind. Somit stellen sie einen genetischen Ansatz 
zur Untersuchen der Kausalität zwischen einem Biomarker und einer Erkrankung dar. Die 
Assoziationen zwischen genetischen Varianten des Kandidatenortes und Typ 2 Diabetes wurden den 
Ergebnissen einer von DIAGRAM, einem großen Diabetes- und Genetikkonsortium, veröffentlichten 
Metaanalyse von acht GWAS (8,130 Fälle, 38,987 Kontrollen) entnommen. Sie waren trotz 
ausreichender Power nicht signifikant, was darauf hinweist, dass es genetische Mechanismen gibt, die 
A-SAA Spiegel erhöhen, ohne zu einem Anstieg des Typ 2 Diabetesrisikos zu führen. 
Zusammenfassend zeigen die Ergebnisse dieser Dissertation, dass A-SAA Spiegel Jahre vor der 
Entstehung von Typ 2 Diabetes erhöht sind, dass der Zusammenhang aber tatsächlich kausal ist, 
konnte mithilfe eines genetischen Ansatzes nicht gezeigt werden. Es scheint vielmehr wahrscheinlich, 
dass der Zusammenhang zwischen A-SAA Spiegeln und Typ 2 Diabetesrisiko wesentlich  durch post-
challenge Hyperglykämie beeinflusst wird. Zeit-Reihen Studien sind erforderlich, um die Rolle von 
post-challenge Hyperglykämie in diesem Zusammenhang zu klären. 
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1. Scientific Background 
1.1. Type 2 diabetes 
1.1.1. Overview of type 2 diabetes  
Diabetes mellitus  
Diabetes mellitus is a heterogeneous group of metabolic disorders characterized by chronic 
hyperglycemia [1]. First classical symptoms of diabetes mellitus are weight loss, polyuria, polydipsia 
and blurring of vision [2]. They may be absent or not severe for a long time before diabetes mellitus is 
diagnosed. Diabetes mellitus may cause severe long-term micro- and macrovascular damage 
eventually leading to the dysfunction or failure of heart, blood vessels, eyes, kidney and nerves [1, 2]. 
The clinically most relevant consequences of untreated diabetes mellitus are retinopathy and 
blindness, diabetic nephropathy and renal failure, neuropathy and foot ulcers, amputations, and 
autonomic dysfunction, stroke, coronary artery and peripheral vascular disease [1-3].  
 
Types of diabetes mellitus 
Based on etio-pathogenesis diabetes mellitus can be classified into different types [1, 2]. Type 1 
diabetes is characterized by deficient insulin production primarily caused by an immune-mediated 
destruction of pancreatic β-cells. It accounts for about 5 % of diabetes mellitus cases. Type 2 diabetes 
comprises about 90 % of all diabetes mellitus cases thus constituting the most common form of 
diabetes mellitus. It is mainly the result of a decreased insulin sensitivity which may not be 
compensated for by an increased insulin secretion at a later stage of disease pathogenesis. Another 
type of diabetes mellitus is gestational diabetes with a prevalence of 2-5 % among pregnant women in 
Europe. It is characterized by a carbohydrate intolerance resulting in hyperglycemia with onset or first 
recognition during pregnancy. Further types of diabetes mellitus include late-onset autoimmunity 
diabetes in the adult (LADA) which is a slow-onset metabolic disorder with characteristics of type 1 
diabetes, other types of diabetes mellitus prone to genetic defects in insulin action or the β-cells such 
as maturity-onset diabetes in the young (MODY), diseases of the exocrine pancreas, endocrinopathies, 
and chemically or pharmaceutically induced impairments of glucose homeostasis [1, 2]. 
 
Diagnostic criteria for type 2 diabetes 
Type 2 diabetes can be diagnosed on the basis of an oral glucose tolerance test (OGTT). In an OGTT, 
venous plasma glucose levels are measured in the fasting state and 2 hours after the intake of 75 g 
anhydrous glucose [1, 4]. Additionally, type 2 diabetes can be diagnosed based on the presence of 
classical symptoms of hyperglycemia (weight loss, polyuria, polydipsia, and blurring of vision) 
accompanied by occasionally elevated venous plasma glucose concentrations [1, 4]. An impaired 
glucose homeostasis may be present a long time before the onset of type 2 diabetes. It may appear in 
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two pre-diabetic conditions of intermediate hyperglycemia, impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT). Individuals with IFG or IGT are at high risk for developing type 2 
diabetes as well as long-term complications [1, 4, 5]. Therefore, the identification of these individuals 
is of major importance. Like type 2 diabetes, the two pre-diabetic conditions IFG and IGT can be 
diagnosed on the basis of an OGTT [6]. Cut-off levels of venous plasma glucose for the diagnosis of 
type 2 diabetes and intermediate hyperglycemia according to the current recommendations of the 
World Health Organization (WHO) [4] are presented in Table 1.  
Differing from WHO recommendations, the American Diabetes Association (ADA) recommends a 
lower fasting venous plasma glucose cut-off value of 100 mg/l (5.6 mmol/l) for the diagnosis of IFG  
to meet a potential clinical relevance in particular for individuals at high risk [6, 7]. 
 
Table 1. Cut-off levels of venous plasma glucose for the definition and diagnosis of type 2 
diabetes and intermediate hyperglycemia 
  Type 2 diabetes IFG IGT 
Fasting glucose 
≥ 126 mg/dl  
(≥ 7.0 mmol/l) 
110-125 mg/dl  
(6.1-6.9 mmol/l) 
< 126 mg/dl  
(< 7 mmol/l) 
  or and and 
2h-glucose 
≥ 200 mg/dl  
(≥ 11.1 mmol/l) 
< 140 mg/dl  
(< 7.8 mmol/l) 
140-199 mg/dl  
(7.8-11.0 mmol/l) 
Random glucose* 
≥ 200 mg/dl  
(≥ 11.1 mmol/l)   
 
IFG= impaired fasting glucose, IGT= impaired glucose tolerance 
* In patients with classical symptoms of hyperglycemia or hyperglycemic crisis 
 
 
HbA1c - another diagnostic marker for type 2 diabetes? 
Recently, the ADA also expanded its recommendations for the diagnosis of type 2 diabetes to 
hemoglobin A1c (HbA1c) and defined HbA1c values ≥ 6.5 % as clinically relevant for the diagnosis 
of type 2 diabetes [6]. HbA1c is the percentage of the glycated fraction of hemoglobin. It is primarily 
measured to identify the average plasma glucose concentration over a prolonged period of time (2-3 
months). Thus, it constitutes a useful measure for monitoring the progress of diabetes mellitus in 
therapy [4, 8]. The major advantage of measuring HbA1c is that it does not require fasting blood 
probes or an OGTT and that it integrates both, fasting blood glucose concentrations as well as peaks 
of post-prandial blood glucose concentrations. However, the definition of type 2 diabetes on the basis 
of HbA1c has been discussed controversially [4, 6, 8, 9]. Apart from higher costs, the diagnosis of 
type 2 diabetes on the basis of HbA1c values leads to a different classification of type 2 diabetes cases 
compared to the diagnosis based on an OGTT [10] with implications for the individual and population 
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prevalence estimates. Moreover, it has been shown that the association between levels of blood 
glucose and HbA1c may be different in different ethical populations [4, 11].  
 
Epidemiology of type 2 diabetes  
Before presenting prevalence and incidence estimates for type 2 diabetes, it should be noted that 
global estimations are based on country reports which may differ in quality. Furthermore, for several 
countries no population-based data on diabetes prevalence and undetected cases are available making 
it hard to estimate global prevalence and incidence precisely [12]. However, dimensions and 
tendencies are without controversy.  
According to estimations of the International Diabetes Federation (IDF), the global prevalence for 
diabetes and IGT in adults aged 20-79 years was 8.3 % which corresponds to some 366 million people 
in 2011 [13]. These estimations include 50 % undiagnosed or unreported diabetic cases [13]. Country-
specific estimates for diabetes prevalence vary with most diabetic people living in the economically 
less developed regions [13]. 
Diabetes prevalence has increased dramatically in the past and is expected to rise further in the future. 
It is assumed that this development is possibly driven by population growth and aging, increasing 
urbanization, dietary changes, and a reduced physical activity [14, 15]. Data extrapolation resulted in 
an estimated rise in global prevalence to 9.9 % corresponding to 522 million individuals with manifest 
diabetes by 2030 [13]. This equates to a cumulative incidence of ten million cases per year [13]. Like 
prevalence numbers incidence rates are geographically heterogeneous; whereas the increase in type 2 
diabetic patients between 2010 and 2030 is estimated to be 20 % in Europe, it is estimated to be 42 % 
in North America and even 72-98 % in Africa, the Middle East, and South-East Asia [13].  
In Europe, the number of diabetic people is thought to be 52.6 million corresponding to 8.1 % of the 
adult population [13]. Thus, Europeans have a moderate prevalence of diabetes compared to other 
ethnic groups. Similarly, in Germany the number of diabetic patients was estimated to be about 8.2 % 
(95 % confidence interval (CI), 7.3-9.2 %) of the adult population [16]. Within Germany, the 
prevalence of diabetes is geographically heterogeneous and dispays an imbalanced gradient from 
North to South and from East to West with highest prevalence in North-East Germany [16]. In a 
population-based study conducted in the region of Augsburg, Southern Germany, about 50 % of type 
2 diabetes cases was previously undetected and newly diagnosed in participants aged 35 years and 
older [17, 18]. However, due to the geographical differences in the German population, these data 
estimates may not be extrapolated to the whole of Germany. Moreover, the described study did not 
differentiate between the different types of diabetes making it difficult to define the proportion of 
estimates attributed to type 2 diabetes.  
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1.1.2. Type 2 diabetes risk factors 
Epidemiological studies have provided evidence for a variety of different type 2 diabetes risk factors 
[19]. These risk factors can be classified into non-modifiable and modifiable risk factors. The most 
important non-modifiable risk factors are age and genetic predisposition; adiposity and physical 
inactivity are the most relevant modifiable risk factors [20].  
 
Age 
Globally, the prevalence of type 2 diabetes and glucose intolerance increases with age [13, 21, 22]. 
Results of time-series analyses conducted in 6,538 participants (35-55 years of age) of a prospective 
cohort study (the Whitehall-II study) showed a decrease in insulin sensitivity with age during 13 years 
of follow-up and thus provided evidence for a direct association between age and insulin sensitivity 
[23]. In some studies, however, the decrease in insulin sensitivity with age was attributed to an 
increase in intra-abdominal fat [24, 25]. Contrary to the findings on insulin sensitivity, deficiencies in 
ß-cell function had been consistently demonstrated in aging humans independent of adiposity 
measures [25, 26]. 
 
Genetic determinants 
A comparison of type 2 diabetes prevalence across different ethnicities living in a similar environment 
suggests a possible genetic contribution to the pathogenesis of type 2 diabetes [27, 28]. For example, 
Asian Americans have been reported a 60 % higher type 2 diabetes prevalence adjusted for body-mass 
index (BMI) than non-Hispanic white Americans in a great population-based survey conducted in the 
United States [27]. Moreover, family studies have shown that first degree relatives of individuals with 
type 2 diabetes are about 3 times more likely to develop the disease than individuals without a 
positive family history [29]. Up to now, more than 50 genetic susceptibility loci for type 2 diabetes 
have been identified [30-32]. Of those, common variants of the transcription factor 7-like 2 gene 
(TCF7L2) showed the strongest replicated effect on type 2 diabetes risk across different ethnicities 
with odds ratios (OR)s varying between 1.3 and 1.6 in an additive genetic model [33-36]. The 
majority of type 2 diabetes genetic susceptibility loci has been identified in large genome-wide scans, 
only two, potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11), and peroxisome 
proliferator-activated receptor gamma (PPARγ), were reproducibly found in candidate gene studies 
(chapter 1.3.2) [37, 38]. Although the identified type 2 diabetes susceptibility loci explain only about 
10 % of the estimated heritability so far [30, 39], some insights have been gained. For one thing, 
results of genetic studies on type 2 diabetes demonstrated that the primary genetic effect on type 2 
diabetes susceptibility seems to be mediated through deficiencies in insulin secretion rather than 
insulin action [37, 40]. Moreover, some of the identified type 2 diabetes loci also harbor rare 
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mutations that are causal for monogenic types of diabetes or exert pleiotropic effects indicating an 
overlap in disease etiology [40].  
 
Adiposity and physical inactivity 
The most important modifiable type 2 diabetes risk factor is adiposity. In addition to adiposity per se, 
lifestyle and environmental conditions such as chronic excess nutrition and physical inactivity 
contributing to adiposity are of major relevance in the context of type 2 diabetes [41, 42].  
Adipose tissue is an endocrine organ and releases amongst others free fatty acids, hormones, pro-
inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), and 
acute-phase reactants like plasminogen activator inhibitor-1 (PAI-1) and serum amyloid A (SAA) [43-
46]. These adipokines interfere with different metabolic pathways which might induce, promote or 
influence adverse metabolic conditions contributing to type 2 diabetes pathogenesis (see also 1.2.1.). 
Generally used measures for adiposity include BMI and waist-to-hip ratio (WHR). BMI is calculated 
as weight [kg] divided by the square of height [m] and is a measure of adiposity regardless of body fat 
distribution. In contrast, WHR is the ratio between the circumferences of the waist to that of the hip 
and reflects abdominal fat. The question which adiposity measure is more strongly associated with 
type 2 diabetes has been discussed controversially [47-49]. 
Large part of type 2 diabetes risk is attributable to adiposity. For example, in a multi-ethnic cohort 
study conducted in 74,970 subjects aged between 45 and 75 years of Caucasian, Native Hawaiian, and 
Japanese American ethnicity about half of the incident type 2 diabetes cases were calculated to be 
attributed to a BMI ≥ 25 kg/m² [50]. Closely related to adiposity is physical inactivity. According to a 
global estimation of the year 2012, physical inactivity accounted for 7 % (95 % CI, 3.9-9.6) of type 2 
diabetes cases [51]. It is thought that physical activity directly impacts on glucose homeostasis via 
activation of glucose transporters in muscle and adipose tissue as well as enhanced glycogen synthase 
resulting in an increased non-oxidative disposal of glucose [52-54].  
 
Further type 2 diabetes risk factors 
Apart from these risk factors several more type 2 diabetes risk factors have been identified. For 
example, active and passive smoking [55, 56] and non-moderate alcohol intake [57] constitute two 
more modifiable lifestyle risk factors.  
Moreover, low birth weight reflecting fetal malnutrition has been found to be associated with IGT and 
type 2 diabetes pointing towards an influence of intrauterine environment on the development of type 
2 diabetes later in life [58, 59].  
In the last years, evidence arose that also psychosocial factors play a role in the development of type 2 
diabetes. It has been shown that job strain, depression, or - closely connected to both - quality of sleep 
contribute to diabetes risk [60-63]. Furthermore, low education, low income and low employment all 
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of them representing a low socio-economic status were found to be significantly associated with an 
increased type 2 diabetes risk in industrialized countries [64-67].  
Finally, prospective studies have shown an inverse association between serum 25-hydroxyvitamin D 
and insulin resistance [68, 69]. 
 
Prevention of type 2 diabetes via reduction of modifiable risk factors 
Representing targets for primary prevention, type 2 diabetes risk factors that are at least in part 
modifiable are of major public health relevance [50, 52, 70-72]. Several intervention studies aiming 
on the reduction of weight, a balanced diet with a low total intake of fat and saturated fat and an 
increased intake of fiber, as well as an increased physical activity demonstrated a significantly 
reduced progression of type 2 diabetes in individuals at high risk. For example, an intervention study 
conducted in 557 Chinese subjects with IGT who were randomly assigned to a diet group, an exercise 
group, a diet-and-exercise group, and a control group showed a significant more than 30 % reduction 
in risk for developing type 2 diabetes within 6 years of follow-up in any of the intervention groups 
compared to the control group [73]. In another intervention study, the Finish Diabetes Prevention 
Study, conducted in 522 overweight subjects with IGT a randomly assigned intervention group 
received individualized counselling aimed at reducing weight by diet and physical activity. In this 
group, the risk for developing type 2 diabetes was reduced by 58 % within 3.2 years compared to a 
control group [74].  
 
 
1.1.3. Pathogenic mechanisms of type 2 diabetes 
Given the diversity of factors contributing to type 2 diabetes risk the question arises whether all these 
risk factors are based on certain common underlying concepts [20]. 
 
Framework of glucose homeostasis 
In order to understand putative concepts, it is necessary to first describe the principal framework of 
glucose homeostasis. In normoglycaemic subjects, levels of blood glucose are sustained stable within 
a narrow range between 60-126 mg/dl. Insulin is the key hormone for the regulation of blood glucose 
and in a healthy organism normoglycaemia is maintained by the balanced interplay between insulin 
action and insulin secretion [75]. Insulin is synthesized in the ß-cells within the islets of Langerhans, 
an endocrine region of the pancreas. It is secreted directly in the blood flow and exerts its effect on 
insulin-dependent cells through binding to insulin receptors on the surface of the cells. The insulin 
receptor in return phosphorylates itself and several substrates thus starting the downstreaming 
signaling and promoting the uptake of glucose into peripheral insulin-depending tissue such as muscle 
and adipose tissue [76, 77]. Furthermore, insulin inhibits hepatic glycogen breakdown and 
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gluconeogenesis. Insulin resistance is a state in which the effect of insulin on its target cells is less 
than expected. It can be partly compensated for as healthy pancreatic ß-cells can adapt to changes in 
the insulin action [78, 79]. This means that a decreased insulin action is compensated by a higher 
insulin secretion. However, the compensatory concept does not work unlimited. When insulin action 
decreases, concentrations of blood glucose increase and although this increase may be small, over 
time it promotes glucose toxicity and eventually leads to ß-cell dysfunction in itself [75]. Time-series 
analyses in the Whitehall-II study showed that the insulin sensitivity decreased slightly in all 
participants during the 13 years of follow-up, while ß-cell function displayed a short increase 
followed by a rapid decrease in incident type 2 diabetes cases four years before diagnosis [23]. This 
demonstrates that ß-cell dysfunction is a critical feature in type 2 diabetes pathogenesis.  
 
Pathogenic mechanisms 
The main mechanisms to explain insulin resistance and ß-cell dysfunction discussed today are 
glucotoxicity and lipotoxicity. These features describe the pathological consequences of increased 
glucose and lipid concentrations in blood. On an intracellular level, glucotoxicity and lipotoxicity 
might possibly lead to mitochondrial dysfunction and an increase of reactive oxidative species (ROS), 
endoplasmic reticulum stress, and subclinical inflammation [80-82]. 
Hyperglycemia may affect different metabolic pathways, molecules, and cells, thus increasing the risk 
for the development of type 2 diabetes as well as micro- and macrovascular complications of the 
disease. For example, it is thought to activate protein kinase C (PKC) isoforms, increase levels of 
glucose-derived advanced glycation end products, and to increase glucose flux through the aldose 
reductase pathway in vascular endothelium and in adipocytes [83]. Beside other effects, ultimately, 
these features might possibly result in an increase of mitochondrial ROS as well as an activation of 
pro-inflammatory signaling [83, 84].  
Lipotoxicity is caused by an imbalance between the production of lipids and their oxidation or 
transport. This imbalance may lead to amplification, functional disturbance, and morphological 
changes in adipose tissue as well as ectopic lipid deposition in the muscle, liver, and pancreas with 
functional implications for these tissues [85].  
Mitochondrial dysfunction is thought to be one of the results of an intracellular increase of 
triglycerides and concentrations of intermediate metabolites related to lipid metabolism as a 
consequence of deficient lipid oxidization. Mitochondrial dysfunction is assumed to activate pro-
inflammatory signaling and to inhibit insulin signaling resulting in a reduced uptake of glucose in 
target cells [85-88]. Thus, mitochondrial dysfunction is discussed to represent the linking mechanism 
between lipotoxicity and insulin resistance.  
ROS is assumed to be a by-product of mitochondrial respiration during times of excess intracellular 
nutrient availability. Amongst others, an increase of ROS possibly causes endoplasmic reticulum 
stress. Endoplasmic reticulum stress is characterized by slow protein folding and, ultimately, an 
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unfolded protein response which in return possibly leads to additional production of ROS. This has 
been studied in different cell lines including adipocytes [84, 89]. Moreover, endoplasmic reticulum 
stress has also been reported to be present in pancreatic ß-cells, especially in insulin resistant 
individuals where the flux of proteins through the endoplasmic reticulum is higher compared to 
normoglycaemic individuals [90]. Endoplasmic reticulum stress is thought to possibly lead to reduced 
insulin sensitivity as a consequence of a reduced ability to increase glucose uptake in response to 
insulin [91]. Furthermore, it is assumed to trigger the activation of inflammatory signaling by 
activating nuclear factor κB (NF-κB) which in return may possibly lead to the induction of several 
cytokines like IL-6 and the suppression of insulin signaling in insulin-dependent target cells [91]. 
 
Subclinical inflammation seems to be a common feature in the concepts described. Moreover, many 
type 2 diabetes risk factors such as adiposity, physical activity, alcohol intake, and lipids, but also risk 
factors which are not prone to excess or malnutrition like age, psychosocial stress, and quality of sleep 
have been reported to be correlated with inflammatory markers [20]. Therefore, it has been postulated 
that type 2 diabetes might actually be an inflammatory disease [92].  
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1.2. Acute-phase serum amyloid A – a measure of subclinical inflammation 
1.2.1. Subclinical inflammation  
Inflammation is the first innate immune response to inflammatory stimuli such as injury, infection, 
trauma, and stress. The cardinal signs of inflammation are redness, swelling, heat, pain, and loss of 
function. In healthy individuals, the acute inflammatory process is transient and has mainly beneficial 
effects in restoring homeostasis. However, inflammation is a “friendly fire” [93]. Persistent, excessive 
or recurrent inflammatory stimuli may result in chronic subclinical inflammation, a condition of a 
low-graded increase of immune mediators in blood in individuals without classical symptoms of 
inflammation [92, 94, 95]. It is thought that subclinical inflammation may affect the body’s 
susceptibility to a number of severe chronic diseases such as type 2 diabetes, atherosclerosis and their 
clinical complications [93-95].  
 
Evidence for an implication of subclinical inflammation in type 2 diabetes 
First evidence of an association between subclinical inflammation and type 2 diabetes was given 
about 50 years ago in the early 1960s when cross-sectional studies found that immune mediators were 
up-regulated in type 2 diabetic cases [96]. Later studies presented evidence that a large range of 
immune mediators are already up-regulated in individuals with IGT and years before the onset of 
overt type 2 diabetes. These immune mediators include high sensitivity-C reactive protein (hs-CRP), 
IL-6, TNF-α, leucocyte count, interleukin-1 (IL-1), PAI-1, factor VIII, von Willebrand factor, 
orosomucoid, fibrinogen, sialic acid, and gamma-globulin [94, 95]. The prospective studies provided 
a hint that subclinical inflammation might be a cause rather than a consequence of the disease. This 
might be the case particularly in women: In a case-cohort study conducted in 7,936 subjects aged 35-
74 years at baseline who participated in the population-based Monitoring of Trends and Determinants 
in Cardiovascular Disease/Cooperative Research in the Region of Augsburg (MONICA/ KORA) 
study, it has been shown that the association between hs-CRP and incident type 2 diabetes was sex 
specific and more pronounced in women [97]. However, not all cross-sectional and prospective 
studies stratified their analyses by sex. Furthermore, results of some studies have been partly 
conflicting regarding confounding by adiposity measures and baseline glycaemia [98].  
Genetic association studies further supported a pathogenic role of immune mediators in type 2 
diabetes as they reported associations between diabetes and polymorphisms in functional regions of 
genes involved in the immune response such as in the promoter region of the pro-inflammatory 
cytokines TNF-α and IL-6 [99-102]. Furthermore, the Ala allele of the common Pro12Ala 
polymorphism in isoform 2 of PPARγ has been robustly found to be associated with reduced risk for 
type 2 diabetes in numerous studies [103]. PPARγ is a transcription factor with some anti-
inflammatory activities. The reduction in transcriptional activity of PPARγ is thought to modulate the 
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production and release of adipose-derived factors, including the pro-inflammatory cytokine TNF-α as 
well as resistin which has been shown to increase the expression of several pro-inflammatory 
cytokines [104].    
Moreover, immune gene disruption or transgenic overexpression of immune mediators have been 
found to be associated with protection from diabetes or higher diabetes prevalence in animal studies 
[95]. For example, the absence of TNF-α improved insulin sensitivity in obese mice and protected 
from the obesity-related reduction in insulin receptor signaling in muscle and fat tissue of these 
animals [105]. In another study, mice lacking the gene encoding PAI-1 were protected from 
developing obesity and insulin resistance after a high-fat diet [106].  
Finally, a number of intervention studies showed a decrease in inflammatory mediators after weight 
reduction and/ or improved physical activity which was correlated with an improved glucose 
metabolism [95]. For example, one study conducted in 19 obese and 10 lean men (initial mean BMI 
38.6 kg/m², SD 0.6 kg/m² and 23.4 kg/m², 0.4 kg/m², respectively) found a correlation between 
changes in IL-6 but not interleukin-8 (IL-8) with an improved insulin sensitivity after 16 weeks of 
energy-restricted diet and a subsequent weight loss in the obese men [107]. Intervention studies also 
reported on a decrease in inflammatory mediators after the treatment with anti-diabetic agents. In a 
review on inflammation and type 2 diabetes Kolb and Mandrup-Poulsen (2005) presented evidence 
for an effect of sulphonylurea on TNF-α, metformin on hs-CRP, glitazones on hs-CRP, SAA, TNF-α, 
soluble CD40 ligand, and PAI-1, and insulin on hs-CRP, IL-1, TNF-α, soluble intercellular adhesion 
molecule-1 (ICAM-1), monocyte chemotactic protein-1 (MCP-1), and PAI-1 [95]. However, 
interventions need to target inflammatory or glucose pathways only and may not have pleiotropic 
effects to allow deductions on the direction of causation. For example, in a randomized controlled trial 
undertaken in 27 type 2 diabetic subjects (mean age 63.0 +/- 1.7 years, HbA1c 8.8 +/-0.3 %, BMI 
32.7 +/- 0.8 kg/m2, therapy duration 15.2 +/- 1.4 years, insulin dose 73.3 +/-7.0 U/day) receiving 
daily either 400 mg troglitazone or placebo for 16 weeks glucose metabolism was improved and 
levels of circulating SAA were decreased in the intervention group [108]. Troglitazone acts as insulin 
sensitizer and has been found in cell lines and animal models to decrease hepatic glucose output by 
decreasing the rate of gluconeogenesis in the liver or by increasing glycolysis [109]. Being a ligand 
particularly to PPARγ it has also been found to be associated with a decrease of NF-κB and an 
increase of IκB thus modulating the transcription of a number of pro-inflammatory genes [110, 111]. 
The implications of troglitazone into both, glucose metabolism as well as inflammation, make it 
difficult to determine cause and consequence. 
  
Inflammatory pathways in insulin signaling 
Several inflammatory pathways which are initiated by extracellular mediators like cytokines and 
lipids as well as by intracellular conditions like endoplasmic reticulum stress and ROS are thought to 
lead to the attenuation of insulin signaling and insulin action (Figure 1).  
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Figure 1: Attenuation of insulin signaling and insulin action by post-translational modification of 
insulin receptor substrates. Modified according to Schmid MI et al., 2005 [112].  
FFA - free fatty acids; IL-6 -  interleukin-6; TNA-α - tumor necrosis factor-α, JNK – JunkN-terminal 
kinase, IKK – inhibitor of NF-κ B kinase, PKC-θ  -protein kinase C-θ, iNOS -  inducible nitric oxide 
synthase, NO – nitric oxide, SOCS-3 – suppressor of cytokine signaling 3, IRS-1 and 2 – insulin 
receptor substrate 1 and 2. 
 
 
It has been shown in vitro that exposure of cells to the pro-inflammatory cytokine TNF-α stimulates 
the phosphorylation of serine residues of the insulin receptor substrate-1 (IRS-1) which prohibits both 
tyrosine phosphorylation of IRS-1 in response to insulin and the ability to associate with the insulin 
receptor [113]. Several kinases including Junk N-terminal kinase (JNK), inhibitor of NF-κB kinase 
(IκB), and protein kinase C-θ (PKC-θ) are thought to be essential to the inflammatory signaling. 
These kinases possibly activate inflammatory gene expression as well as directly inhibit insulin 
signaling [85, 94]. Furthermore, members of the protein suppressor of cytokine signaling (SOCS) 
family have been found to be implicated in inflammation-induced insulin resistance in cell line studies 
and animal models [85, 94]. It is hypothesized that they inhibit insulin signaling by interfering with 
IRS phosphorylation or proteosomal degradation [114]. Moreover, inflammation is discussed to lead 
to an overproduction of nitric oxide which is thought to contribute to both, reduced insulin sensitivity 
in muscle cells as well as an impaired ß-cell function [85]. The modulation of these pathways might 
connect subclinical inflammation with insulin resistance and reduction in β-cell mass. 
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Inflammation and loss of ß-cell function 
Amyloid deposition has been reported to be present in type 2 diabetes pancreatic islet tissue [90]. 
Furthermore, it has been shown that levels of cytokines and chemokines were up-regulated in 
pancreatic islets of patients with type 2 diabetes and also animal models consistently revealed an 
infiltration of immune cells in type 2 diabetes pancreatic islets [90]. All these points towards an 
implication of inflammation into the loss of ß-cell function. One possible mechanism is the 
interleukin-1ß (IL-1ß)/ NF-κB pathway [115]. It is assumed that exposure to prolonged or recurrent 
high glucose levels increases the production of IL-1ß at large extents which in return promotes Fas-
triggered apoptosis partly via NF-κB activation [115]. Furthermore, it possibly increases the number 
of cytokines leading to enhanced infiltration of macrophages, which in return might then further 
induce IL-1ß expression as well as other cytotoxic factors possibly responsible for ß-cells dysfunction 
and failure [90]. The process is thought to be amplified by IL-1ß capacity of auto-induction as well as 
by the presence of free fatty acids which further increase IL-1ß expression and the release of IL-6 and 
IL-8 in pancreatic islets [90]. 
 
 
1.2.2. Acute-phase serum amyloid A  
This chapter is partly extracted from the manuscripts Marci C. et al., Acute-phase serum amyloid A 
protein and its implication in the development of type 2 diabetes in the KORA S4/ F4 study, 
Diabetes Care, 2012 Dec 13, epub ahead of print, and Marzi, C. et al., Genome-Wide Association 
Study Identifies Two Novel Regions at 11p15.5-p13 and 1p31 with Major Impact on Acute-Phase 
Serum Amyloid A, PloS Genetics PLoS Genet. 2010 Nov 18;6(11):e1001213. 
 
SAA protein is a sensitive marker of subclinical inflammation. It is an apo-lipoprotein mainly 
associated with high-density lipoprotein (HDL) in plasma. SAA isoforms are expressed constitutively 
(C-SAA) and show a rapid increased expression in response to inflammatory stimuli such as infection, 
tissue injury, trauma, and stress during the acute phase (A-SAA) [116, 117]. The high inductive 
capacity along with a high conservation of genes and proteins throughout evolution of vertebrates and 
invertebrates suggests that A-SAA plays a key role in pathogen defense and probably functions as an 
effector molecule of the immune-system [116]. 
 
Functional aspects of A-SAA 
The precise role of A-SAA proteins in host defense during inflammation has not been completely 
elucidated so far. Three potential clinically important functions are proposed. First of all, A-SAA 
proteins have been found to induce extracellular-matrix degrading enzymes such as collagenase, 
which are essential in repair processes after tissue damage. Furthermore, A-SAA seems to be involved 
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in lipid metabolism and transport by reversing cholesterol transport to supply lipid to peripheral cells 
that may have an increased requirement for tissue regeneration at the inflammatory site or, 
alternatively, by facilitating the removal of cholesterol liberated at sites of tissue damage during 
inflammation. Finally, A-SAA is assumed to have chemotactic properties and to recruit inflammatory 
cells such as monocytes, leukocytes, mast cells and T-lymphocytes to sites of inflammation. 
Summarized according to Uhlar and Whitehead, 1998 [116]. 
 
A-SAA expression and regulation 
Serum concentrations of A-SAA increase by up to a 1000-fold within 24h in response to 
inflammatory stimuli such as infection, injury, trauma, and stress [116]. The expression of A-SAA 
during the acute-phase is summarized in Figure 2.  
 
 
 
 
 
 
 
Figure 2: A-SAA expression during the acute-phase. Modified according to Uhlar, CM and 
Whitehead, AS, 1999 [116]. IL-6 – interleukin-6, TNF-α – tumor necrosis factor-α, NF-κB – nuclear 
factor-κB, C/EBP – CCAAT/ enhancer binding protein, YY1 – ying and yang 1 
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A-SAA expression is induced by pro-inflammatory cytokines including IL-1, TNF-α and IL-6 as well 
as glucocorticoids [116-119]. The dramatic induction of A-SAA mRNA during the acute-phase is 
probably mainly attributed to the synergistic effects of cytokine signaling pathways, particularly those 
of IL-1 and IL-6 type cytokines after the recruitment of macrophages to the inflammatory site [116]. 
Inflammatory cytokines are also thought to increase glucocorticoid production by the adrenal cortex 
after corticotrophic releasing factor and corticotrophin have been released from the hypothalamus. 
Glucocorticoids may possibly enhance A-SAA synthesis as well as down-regulate the systemic acute-
phase response [116]. Furthermore, A-SAA is supposed to having cytokine-like properties and 
enhancing the induction of pro-inflammatory cytokines itself thus augmenting the immune response 
[116]. Also post-transcriptional mechanisms including changes in mRNA stability and translation 
efficiency are discussed to be involved in the regulation of A-SAA [117]. Several transcription factors 
have been found to engage with A-SAA promoters including NF-κB and CCAAT/enhancer binding 
protein (C/EBP) for the up-regulation and ying and yang 1 (YY1) for the inhibition of A-SAA 
expression [116]. 
On the cellular level, pro-inflammatory cytokines bind to their hepatic receptors thus activating signal 
transduction into the cell. The binding of IL-6 to its receptor is thought to phosphorylate the nuclear 
factor for IL-6 which is possibly subsequently transferred to the nucleus where it might initiate A-
SAA transcription. In addition to this, it might activate the expression of the nuclear factor for IL-6ß 
which in return might further enhance A-SAA expression. The binding of TNF-α and IL-1 to its 
receptors is assumed to lead to the phosphorylation of the cytoplasmic NF-κB-IκB complex resulting 
in the degradation of IκB and the translocation of NF-κB to the nucleus where it might bind to the 
promoter region of A-SAA. At the later stage of the acute-phase response, the expression of A-SAA is 
assumed to be down-regulated via an increased production of cytokine antagonists such as 
interleukin-1 receptor antagonist (IL-1Ra) and soluble cytokine receptors. The A-SAA gene 
transcription may possibly be controlled by the NF-κB-IκB complex. The activation of NF-κB might 
result in an increased transcription of the IκB gene. IκB might subsequently enter the nucleus and 
induce the dissociation of NF-κB from its binding site in the A-SAA promoter. Another putative 
control mechanism for the A-SAA transcription involves the transcription factor YY1 which might 
also contribute to the dissociation of NF-κB from its binding site. The NF-κB-IκB complex is thought 
to be subsequently translocated into the cytoplasm. The reactivation of transcriptions factors is 
thought to be prevented by IL-1Ra which might bind to the IL-1 receptor and thereby stop pro-
inflammatory signal transduction. Summarized according to Jensen and Whitehead, 1998 [117].   
Sometimes, in patients with chronic or recurrent inflammatory conditions such as present in 
rheumatoid arthritis and atherosclerosis, control mechanisms seem to be not sufficient and the long-
term maintenance of some aspects of the acute-phase response may possibly cause subclinical 
inflammatory conditions with chronically elevated levels of A-SAA [116]. Chronically elevated levels 
of A-SAA might also be induced by exposure to allergens or chemicals, physical and mental stress, 
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certain metabolic conditions such as obesity, as well as genetic immune deficiencies and defects in the 
normal control mechanisms [117, 120].  
Like other acute-phase proteins, A-SAA is expressed primarily by the liver [119, 121]. However, 
extra-hepatic expression has been reported for different cells including monocyte, epithelial cells, 
endothelial cells, adipocytes, atherosclerotic lesions, and aortic smooth muscle cells [119, 122, 123]. 
Furthermore, SAA expression has been detected in the brain of patients with Alzheimer disease [124]. 
The broad spectrum of extra-hepatic expression provides a potential local source of A-SAA proteins. 
These proteins may be expressed under conditions independent of the systemic acute-phase response 
and may thus play a role related to the site of expression [119]. 
 
Serum amyloid A gene family 
The SAA gene family is located within 150 kb at chromosome 11 and comprises four genes: SAA1 
and SAA2, the bona fide acute-phase SAA isoforms which code for A-SAA proteins, SAA3, a pseudo-
gene in humans, and SAA4, a low level expressed gene coding for the constitutively expressed C-SAA 
proteins [121, 125, 126]. The alignment of SAA genes on the chromosome is shown in Figure 3.  
 
 
 
Figure 3: The SAA gene family on chromosome 11. Modified according to Sellar GC et al., 1994 
[126]. Arrows within SAA genes represent 5’to 3’ orientation of the gene. The SAA gene family is 
surrounded by the following genes: lactate dehydrogenase A and C (LDHA, LDHC), tryptophan 
hydroxylase (TPH), a member of the potassium channel family (KCNC1), and myogenic factor 3 
(MYOD1). D11S8 is an anonymous human marker. 
 
 
 
SAA1 and SAA2 are both allelic [116, 127]. SAA1 has at least five alleles, three of which encode 
distinct proteins (SAA1.1, SAA1.2, and SAA1.3), and two are neutral polymorphisms of SAA1.1 [116]. 
The alleles are based on two polymorphisms (rs1136743, rs1136747) within exon 3 of the SAA1 gene. 
SAA2 has three alleles: SAA2.1 of which there is a Hind III polymorphism of neutral effect and 
SAA2.2 [116]. The two genes, SAA1 and SAA2, are concurrently induced during the acute-phase [116] 
and cluster within 15-20 kb of each other in a head to head arrangement [128]. The third functional 
gene, SAA4, is located 9 kb downstream of SAA2 in the same direction [129]. Mature protein 
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sequences of SAA1 and SAA2 share greater than 90 % identity [116]. In contrast, the protein sequence 
of SAA4 shares only 53 % and 55 % identities with protein sequences of the human SAA1 and SAA2 
genes, respectively [116].  
While SAA3 expression has been reported in other species such as hamsters and rats [130, 131], the 
human SAA3 gene is a not a functional gene due to a single base insertion in exon 3 and a subsequent 
down-stream stop signal [116].  
Twin studies suggest a substantial genetic contribution to baseline A-SAA concentrations with 
heritability estimates of 59 % (95 % CI, 49–67 %) [132]. However, in the past, association analyses 
between genetic variants and A-SAA levels were limited and restricted to allelic variants of the SAA 
gene family [133, 134]. More studies were set out to investigate the association between genetic 
variants of the SAA genes and amyloidosis (see section below) [135, 136]. These studies revealed 
great ethnic differences suggesting that results of these studies might not be transferable to other 
ethnic groups [135].  
 
Acute-phase serum amyloid A and disease implications  
Numerous studies have shown that prolonged and recurrent chronic infection as well as inflammation 
is causally involved in the pathogeneses of amyloidosis [116]. Amyloidosis is a heterogeneous group 
of disorders characterized by an abnormal amyloid deposition eventually leading to dysfunction and 
failure of the affected tissues and organs. The abnormal amyloid depositions present in amyloidosis 
are presumed to be primarily a consequence of rheumatoid arthritis and Familial Mediterranean Fever. 
[116].  
Apart from its implication in the etiology of amyloidosis, in recent years, clinical and epidemiological 
studies have gathered substantial evidence that A-SAA is associated with obesity. In a meta-analysis 
carried out in 11 cross-sectional studies including a total of 6,993 participants of both genders from 
Canada, USA, Greece, Australia, New Zealand, Finland, the Netherlands, and Belgium SAA and BMI 
were moderately, but significantly correlated with a correlation coefficient of 0.230 (95 % CI, 0.160–
0.297, p < 0.0005). In the same study, the difference in SAA levels before and after weight reduction 
was significant in 10 prospective studies with a total of 353 participants of both genders from Western 
Europe and the USA [120].  
Furthermore, numerous studies suggested that elevated levels of A-SAA induce, promote or influence 
the susceptibility to several chronic diseases such as atherosclerosis and its clinical complications 
[137-145] and various malignancies [146]. For example, in 1,268 initially healthy consecutive patients 
who underwent serial carotid ultrasound investigations at baseline and after about 7 months the ORs 
(95 % CI) for atherosclerosis progression (defined as an increase of the degree of stenosis by at least 
one category with category classes: 0 % to 29 % (carotid plaques), 30 % to 49 % (advanced plaques), 
50 % to 69 % (moderate stenosis), 70 % to 89 % (high-grade stenosis), 90 % to 99 % (subocclusive 
stenosis), and 100 % (occlusion)) for the highest versus the lowest quintile of SAA concentrations 
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was 2.28 (1.24-4.20) [137]. In a case-control study carried out in 506 men with coronary heart disease 
and 1,025 male controls, men at the top third of baseline SAA concentrations had an OR (95 % CI) 
for coronary heart disease of 1.12 (0.71-1.77) compared to those of the lowest third of SAA 
concentrations adjusted for age, town, smoking, vascular risk factors, and indicators of socioeconomic 
status [141]. Finally, in a review on SAA and tumor pathogenesis, evidence was presented that SAA 
was up-regulated around 30-fold in renal cell carcinoma and about two-fold in samples from lung 
cancer patients [146]. 
Cross-sectional data have demonstrated an association between elevated systemic A-SAA 
concentrations and prevalent type 2 diabetes [147, 148] as well as related metabolic parameters [149, 
150]. For example, in a baseline examination of 145 type 2 diabetic Finish subjects between 50 and 75 
years of age SAA was significantly correlated with HbA1c [149, 150]. In another study, a case-
control study (53 type 2 diabetic subjects, 114 controls), the correlations between levels of A-SAA 
and homeostatic model assessment for insulin resistance (HOMA-IR), HbA1c, and insulin were 
significant with correlation coefficients (p-values) of 0.24 (p = 0.002), 0.19 (p = 0.02), and 0.21 (p = 
0.006) [149]. In this study, most of these correlations were more pronounced in women than in men 
suggesting that sex differences should be taken into account when analyzing A-SAA concentrations 
[149].  Furthermore, evidence that circulating levels of A-SAA are not only increased in prevalent 
type 2 diabetes subjects but also in individuals with IGT was presented by comparing 152 type 2 
diabetic subjects, 80 subjects with IGT, and 77 healthy control subjects of the KORA S4 survey [148]. 
However, one study conducted in 492 Aboriginal Canadian subjects investigated whether baseline 
levels of SAA are prospectively associated with type 2 diabetes and did not find evidence for a 
significant association in this study population [151].  
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1.3. Epidemiological perspective and genetic approach  
 
1.3.1. Epidemiology and causal inferences 
Overview of epidemiology 
Epidemiology is the study of the distribution and determinants of diseases frequencies in human 
populations [152]. Briefly, it can be classified into descriptive and analytical epidemiology. 
Descriptive epidemiology assesses disease prevalence and incidences in a population. The analysis of 
associations between putative risk factors and diseases is subject to analytical epidemiology. 
Analytical epidemiology is based on the assumption that diseases do not occur by chance but rather 
by causes which might be identified and at best eliminated [153].  
When interpreting an association between exposure and disease confounding by a third variable 
associated with the exposure and the disease as well as effect modification (i.e. the effect of an 
exposure varies by levels of another variable) have to be considered. In part, this can be accounted for 
in the statistical analysis by multivariate regression and/ or stratified analyses. This is, however, only 
feasible if the confounding variable and/ or the effect modifier is known and has been collected in the 
study investigation. Summarized according to Kreienbrock and Schach, 1995 [154] and Rothman and 
Greenland, 1998 [155] .  
  
Causal inferences 
The hallmark of epidemiological studies is an observational nature. Therefore, causal inferences on 
disease etiology in epidemiological studies have to be drawn with all due caution and require further 
considerations to assess evidence for causation [156]. Those proposed by Sir Austin Bradford Hill in 
1965 are the most frequently used considerations to deduce on causation in epidemiology [157]. One 
of these criteria, temporal relationship, i.e. the chronological order of exposure and disease, is 
implemented in prospective cohort studies (follow-up studies, longitudinal studies). In a prospective 
cohort study, a defined study population during a given period of time (follow-up period) is monitored 
with respect to certain events such as the onset of disease or death. This study is most reasonable 
when analyzing diseases with high incidence rates such as type 2 diabetes. For the identification of 
risk factors, prospective cohort studies compare different risk factor profiles between subjects with 
regard to disease incidence. The temporal relationship which is incorporated in these study type is not 
evidence for causality per se but it is an indispensable prerequisite to it. 
A more distinct indication for causality between a putative risk factor and a disease can be obtained 
by analytical-experimental studies, i.e. clinical trials and intervention studies. In most of these 
studies, participants are randomly assigned to either an intervention or a control group. In order to 
avoid placebo and observation bias participants and study investigators are often blinded, i.e. not 
knowing which participant is assigned to which group. A significant reduction in disease risk in the 
intervention group compared to the control group provides evidence for a causal implication of this 
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risk factor in disease etiology. Summarized according to Kreienbrock and Schach, 1995 [154] and 
Rothman and Greenland, 1998 [155].  
 
 
1.3.2. Genome-wide association studies (GWAS) 
Aims of genetic association studies 
The identification of genetic variants that influence disease susceptibility could help to detect 
previously unknown etiological pathways and may thus provide clues to better understand disease 
pathogenesis and to point towards novel potential targets for intervention [158, 159]. The 
identification of genetic variants involved in a disease might also be of relevance for further sub-
grouping diseases with heterogeneous phenotypes, and this might improve therapy towards a more 
personalized medication approach [160, 161]. In addition, although the genetic predisposition to 
disease is non-modifiable, an improved risk prediction by genetic testing might encourage the 
individual at risk to reduce modifiable risk factors such as high-caloric diet and physical inactivity 
[160]. Finally, the identification of genetic variants that determine biomarker levels is a presumption 
for a Mendelian Randomization study (chapter 1.3.3.). 
 
From candidate gene approach to high-throughput genotyping methods 
In the past, genetic association studies were mainly restricted to certain candidate gene regions which 
were identified in linkage studies or which were by themselves hypothesized to be of relevance for 
certain diseases [162]. In any case, some previous knowledge was required. Since about 2005, 
hypothesis-free testing in genetic association studies has become feasible with the technological 
development of high-throughput/ low-cost genotyping enabling the conduction of GWAS comprising 
a dense set of genetic markers across the whole genome [162, 163].  
 
Chances of GWAS 
Including genetic variants of the whole genome and being hypothesis-free this approach bears the 
chance to detect novel genetic loci involved in pathogenic networks, especially of complex and 
common diseases [164, 165]. It is hypothesized that common diseases in a population (i.e. those with 
a high prevalence) have to be influenced by genetic determinants that are long-standing and thus 
common (i.e. have a high frequency within the population). This assumption has become known as 
the common-disease/ common-variant hypothesis [166, 167]. The common disease/ common variant 
hypothesis implies that genetic determinants of common phenotypes should be found in studies of 
large sample size even if the attributable risk may be small [166, 168]. Indeed, several hundred 
genetic susceptibility loci for different phenotypes have been identified in the past [169] and the 
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capacity to undertake GWAS has already largely improved the understanding of the genetic basis of 
common complex phenotypes [165]. 
The major challenge of GWAS is the identification of true causative variants. There are three possible 
reasons for a statistically valid association between a single-nucleotid polymorphism (SNP) and a 
phenotype: (i) the SNP is causally involved in disease etiology, (ii) the SNP is in linkage 
disequilibrium (LD) with a causal SNP, or (iii) the association is per chance or a false-positive signal 
[158]. False positive findings may be the result of (i) genotyping or imputation errors, (ii) population 
stratification, or (iii) insufficient multiple testing [158]. 
 
(i) Genotyping and imputation 
In spite of all technological advances in the development of high-throughput genotyping it is currently 
not possible to cover all known variation in the human genome at reasonable cost. Therefore, it is 
possible that the causative genetic variants of a disease are not typed on the SNP-chip [169-171]. 
Genotyping chips differ in the way in which the SNPs are chosen and the total number of SNPs 
assayed, i.e. in coverage of SNPs [169]. The selection of SNPs for the chip design can be based on 
chance, on a physically consistent distribution across the whole genome, or based on selection 
methods accounting for LD structures [158] with implications for the power to detect putative 
causative variants as well as for the analyses in different ethnical populations [169].  
To ensure high genotyping quality stringent filtering based on quality scores is necessary [172] and 
those SNPs with a low genotyping call rate which is an indicator for poor DNA quality should be 
excluded from the data set [173]. Furthermore, those SNPs with deviations from Hardy-Weinberg 
Equilibrium (HWE) are likely to be erroneous and should also be excluded from the data set [173].  
Additional information on genetic variation for the genome-wide association analyses can be obtained 
by integrating information of existing catalogs of genetic variation into the analysis [165]. One 
convincing approach for the integration of such information is the imputation method developed by 
Marchini et al., 2007 [174]. The core aim of this method is to predict (or “impute”) the missing data 
based upon the observed genotype data using information on the SNPs directly genotyped and 
combining them with population-based genotype data such as those of the Haplotype Mapping 
(HapMap) consortium and estimates of the fine-scale recombination map across the genome [174]. 
The major advantage of this method is that it uses information from all markers in LD with an 
untyped SNP but in a way that weights genotypes that are consistent with the local patterns of LD 
more and decreases with genetic distance from the SNP being imputed [174]. Population stratification 
(see section below) is a particular concern in the context of imputation methods, because allele 
frequencies and LD patterns between the study sample and the sample used in catalogs of genetic 
variation may differ and reduce the accuracy of the imputation. However, it is assumed that 
approaches to adjust for population stratification should also work for imputed SNPs [174].   
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(ii) Population stratification 
An association between exposure and disease can be biased by confounding. In this context, 
population stratification is of most relevance in GWAS [175-177]. Population stratification is caused 
by population admixture or subgroups within cases or controls which are systematically 
heterogeneous with respect to disease/ phenotype prevalence and allele frequencies [158, 173, 178]. 
The strategy of choice would be to avoid bias induced by population stratification by ensuring that 
study samples are drawn from homogenous populations [173]. Indeed, the importance of population 
stratification as a cause for false-positive findings is thought to be modest if cases and controls are 
well matched for ethnic background and measures are taken to identify and exclude individuals whose 
genome-wide data reveal substantial differences in genetic background [165, 179]. There are also 
statistical approaches to detect and correct for population stratification. These approaches are based 
on the fact that genetic confounding results in deviations from HWE and LD pattern between genetic 
markers on different chromosomes [158]. The mostly used approach to detect and correct for 
population stratification is the genomic control approach [158]. It requires further “neutral” genetic 
markers (i.e. not associated with the phenotype of interest) which can be used to estimate 
substructures. The genomic control approach assesses a scaling factor by which the test statistic is 
extended if population stratification is present [177]. This extension can be taken into account by 
adjusting the test statistic by this scaling factor using different statistical methods [175, 180].  
 
(iii) Multiple testing, power and sample sizes 
In GWAS, the association between SNPs across the whole genome and the disease/ phenotype of 
interest is tested. This results in a large number of tests and thus an increased probability of false-
positive findings (type I errors) [165]. One commonly used method to correct for multiple testing is 
the Bonferroni correction where the level of significance is divided by the number of independent 
tests [181]. However, the Bonferroni correction is over-conservative and leads to an increase in false-
negative findings (type II errors), if there are strong correlations between the independent variables to 
be tested, as is the case for SNPs in LD blocks [165, 181]. As a solution to this problem, information 
on LD structures collected by the HapMap consortium was integrated in power calculations and the 
power was corrected for a million independent tests genome-wide in Europeans, and twice that 
number in Africans [181, 182].  
Given the high dimensionality of GWAS and the resulting multiple testing problem the power to 
detect a statistically significant association between a genetic variant and the phenotype of interest is 
limited and consequently, true positive associations might not be found. In the past, results of GWAS 
showed only small to moderate effects of genetic variants on various phenotypes [183]. The power to 
detect associations at a scale of such small effect sizes is only sufficient if the minor allele frequency 
(MAF) is sufficiently high [173].  
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Power can be boosted by sample size. This fact has led to the formation of large consortia of research 
institutes such as the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium and 
the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC). These consortia 
provide a framework for the combination of several GWAS into large meta-analyses. Meta-analyses 
combine study results either with or without weights (e.g. inverse variance) in random or fixed effects 
models [184]. As the two models are based on the assumption that effects in the single studies are 
homogenous (fixed effects model) or heterogeneous (random effects model) a major point to be 
considered when choosing the appropriate model is between-study heterogeneity and population 
stratification [40, 185, 186]. There are multiple approaches to measure homogeneity between studies 
and consistency of study results [183]. In one approach provided by Higgins et al. in 2003, a quantity 
measure (I²) is assessed that describes the percentage of total variation across studies attributed to 
heterogeneity rather than chance [187]. I² metrics can range between 0 % and 100 % with 0 % 
indicating homogeneity [187].  
 
Replication and multi-stage analysis 
Validation of GWAS has been shown to be essential, firstly, because many initial reports of SNP-
phenotype associations have turned out to be false-positive findings [188] and secondly, because 
almost all initial studies have overestimated the true effect size in the past (“the winners curse”) [189, 
190]. This overestimation of effect sizes is hypothesized to be attributed to bias and genuine 
population diversity [190]. Some studies use a multistage approach to provide replication evidence for 
GWAS findings. At a first stage, SNPs that are associated with a phenotype of interest on a genome-
wide significance level are identified. At a second stage, the identified SNPs are tested in an 
independent replication sample in subsequent analyses [191-193]. A major advantage to this approach 
is that it retains power while reducing genotyping costs [165].  
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1.3.3. Mendelian Randomization Study 
Concept of Mendelian Randomization studies 
Being observational in its nature epidemiological studies are subject to many potential biases, to 
environmental confounding and to reverse causation which limits their ability to robustly identify 
causal associations (see also 1.3.1.) [194]. Mendelian Randomization studies are an approach to 
strengthen causal inferences by using genetic variants as proxy for environmentally modifiable risk 
factors of a disease [194-196]. The concept of a Mendelian Randomization study is displayed in 
Figure 4.  
 
 
 
Figure 4: Concept of a Mendelian Randomization study 
 
 
 
Different alleles of a gene may influence concentrations of the encoded protein via a different degree 
of gene expression activity. If the encoded protein is found to be associated with a specific genetic 
variant as well as a specific disease the genetic variant should also be associated with the disease 
provided that the association between protein and disease is causal [197, 198]. Being based on the 
assumption of a random assortment of genes from parents to offspring, Mendelian Randomization 
studies benefit from a “randomization by nature” and combine the concepts of cohort studies with that 
of randomized controlled trials [199].  
 
Advantages of Mendelian Randomization studies 
There are a number of advantages to this study concept. (i) The random assignment of study 
participants according to their genotypes ensures an equal distribution of potential confounding 
variables such as smoking in the study groups. (ii) Mendelian Randomization studies are double-
1. Scientific Background 
24 
 
blinded, as neither study participants nor investigators usually know the genotype. This averts effects 
caused by placebo and/ or observation bias. (iii) The study concept incorporates the chronological 
order of exposure and disease as the genotype is defined before the onset of the disease so that reverse 
causality is eliminated.  
Generally, Mendelian Randomization studies provide the opportunity to detect associations between 
genetic variants as proxies for intermediate phenotypes and a disease largely unbiased by potential 
environmentally modifying factors [196-198, 200]. Thus, the Mendelian Randomization approach 
might be particularly useful for the identification of causal risk factors for complex diseases 
characterized by multifactorial environmental contributions to pathogenic mechanisms such as type 2 
diabetes.  
 
Limitations 
However, besides these major advantages some limitations should be mentioned. These can be 
summarized to three critical issues [196-198, 200]: 
(i) First of all, a prerequisite of the concept is a suitable genetic variant. This means, that the genetic 
variant within the encoding gene has to be functional otherwise it would not lead to different 
phenotypes. Furthermore, genetic confounding might arise if the genetic variant or another genetic 
variant in LD with it exhibits pleiotropic effects on other intermediate phenotypes associated with the 
disease.  
(ii) Moreover, population stratification, canalization (i.e. the developmental adaption to the 
genetically determined “problem”), selective survival and gene-gene interactions might cause genetic 
confounding.  
(iii) Finally, genetic effects on complex disease phenotypes via intermediate risk factors are usually 
poor and thus large sample sizes are required in order to provide sufficient power to identify gene-
disease associations (section 1.3.2.).  
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2. Outline of the doctoral thesis 
This doctoral thesis aimed to elucidate the association between circulating levels of A-SAA and the 
development of type 2 diabetes in an epidemiological perspective and to assess a possible causal 
implication of A-SAA in the etiology of type 2 diabetes by means of genetics. Three studies were 
conducted: (i) a prospective cohort study entitled Acute-phase serum amyloid A protein and its 
implication in the development of the KORA S4/ F4 study (Marzi et al., Diabetes Care, 2012 Dec 13, 
epub ahead of print), (ii) a meta-analysis of GWAS entitled Genome-wide Association Study Identifies 
Two Novel Regions at 11p15.5-p13 and 1p31 with Major Impact on Acute-Phase Serum Amyloid A 
(Marzi et al., PLoS Genet. 2010 Nov 18;6(11):e1001213), and (iii) a Mendelian Randomization study 
on genetic susceptibility loci for levels of A-SAA and type 2 diabetes (unpublished data). 
 
Prospective cohort study on elevated levels of A-SAA and incident type 2 diabetes 
Cross-sectional data demonstrated a significant association between elevated systemic A-SAA 
concentrations and prevalent type 2 diabetes as well as the related metabolic parameters HOMA-IR, 
fasting insulin, and HbA1c (chapter 1.2.2.). However, only one study conducted in 492 Aboriginal 
Canadian subjects had investigated whether baseline levels of SAA were prospectively associated 
with type 2 diabetes and did not find evidence for a significant association (chapter 1.2.2.). Therefore, 
the prospective cohort study of this doctoral thesis was set out to investigate whether elevated levels 
of A-SAA precede the onset of type 2 diabetes during seven years of follow-up in a large population-
based study of initially non-diabetic, elderly Western European subjects without clinically overt 
inflammation. Moreover, it was assessed whether this association is independent of other type 2 
diabetes risk factors including parameters of glucose metabolism (i.e. fasting glucose, fasting insulin, 
HbA1c, and 2h-glucose) as an indicator for early impairments of glucose homeostasis and whether 
there are differences between men and women as suggested previously (chapter 1.2.1. and 1.2.2.). 
Finally, the strength of the putative association was compared to that between the most frequently 
used inflammatory marker, circulating hs-CRP and incident type 2 diabetes. 
 
Meta-analysis of GWAS on levels of A-SAA 
The identification of genetic variants that determine levels of A-SAA is a prerequisite for a Mendelian 
Randomization study. Furthermore, it might provide important clues to the immune response 
pathways involved in the regulation of A-SAA levels. This might also be of relevance for related 
clinical entities such as type 2 diabetes. Twin studies suggested a substantial genetic contribution to 
baseline A-SAA concentrations but in the past, association analyses between genetic variants and A-
SAA levels had been limited and had been restricted to allelic variants of SAA genes and protein 
concentrations (chapter 1.2.2.). Therefore, the meta-analysis of GWAS of this doctoral thesis was 
designed to analyze the genetic basis of A-SAA levels in a more comprehensive way. In a meta-
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analysis four genome-wide scans (KORA S4, LURIC, TwinsUK and Sorbs) the association between 
genetic variants across the whole genome and circulating levels of A-SAA was analyzed in 4,212 
participants of European descent. Additionally, in order to account for potential sex-specific 
differences in the regulation of A-SAA (chapter 1.2.2.) the analysis was stratified by sex. 
 
Mendelian Randomization study on A-SAA susceptibility loci and type 2 diabetes 
The identification of risk factors that causally contribute to the development of a disease is of 
relevance for the prevention as well as the treatment of a disease. Mendelian Randomization studies 
can be used to assess whether an association between a biomarker and a disease is causal using 
genetic variants as proxies for this biomarker (chapter 1.3.3.). Therefore, in order to analyze whether 
elevated levels of A-SAA causally contribute to the development of type 2 diabetes a Mendelian 
Randomization study was conducted. The associations between genetic variants with the lowest p-
values in the regions/ subregions identified in the meta-analysis of GWAS of this doctoral thesis and 
type 2 diabetes were extracted from a previously published meta-analysis comprising of eight GWAS 
(8,130 type 2 diabetes cases and 38,987 control subjects of European descent). Furthermore, a power 
calculation was conducted to ensure high statistical validity.  
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3. Epidemiological studies 
 
3.1. Acute-phase serum amyloid A protein and its implication in the development of the KORA 
S4/ F4 study 
 
This chapter is modified according to the manuscript Marci C. et al., Acute-phase serum amyloid A 
protein and its implication in the development of type 2 diabetes in the KORA S4/ F4 study Diabetes 
Care, 2012 Dec 13, epub ahead of print. 
 
3.1.1. Research Design and Methods 
 
Study population 
The present study included participants of the population-based KORA Survey S4 (1999-2001, 
N=4,261) and its seven-year follow-up study F4 (2006-2008, N=3,080) and was conducted in the 
region of Augsburg, Southern Germany. The study was approved by the ethics committee of the 
Bavarian Medical Association and informed written consent was obtained from all participants. The 
selection process of study participants is displayed in Figure 5. The sample included all KORA S4 
participants for whom an OGTT was performed at baseline (i.e. only the age group between 55 and 74 
years) and who were non-diabetic according to the OGTT (n=1,231). For the present analyses, 
subjects with elevated levels of hs-CRP at baseline which indicated an acute pro-inflammatory state 
(hs-CRP > 10 mg/l, n = 44) or with missing A-SAA data (n = 16) were excluded. Furthermore, 
participants in the follow-up examination (n = 878) with missing data in type 2 diabetes status (n = 
20) or in one of the co-variates used in the different models (n = 22) were also excluded. Thus, 836 
subjects were included in the present analyses.  
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Figure 5: Flowchart of the selection process of study participants for the present analyses  
 
 
Ascertainment of type 2 diabetes and assessment of independent variables 
Type 2 diabetes was defined on the basis of an OGTT according to the 1999 WHO diagnostic criteria 
[2] or by a self-report which was validated by data on glucose-lowering medication or questioning the 
treating physician. At baseline, fasting EDTA plasma samples were collected and A-SAA was 
analyzed by immunonephelometry on a BN II analyzer using an N Latex enhanced test from Siemens, 
Germany. The inter-assay coefficient of variation was below 7 % [148, 201].  
Information regarding the collection of laboratory, anthropometric, and socioeconomic variables, are 
described in detail elsewhere [17, 97, 202, 203].  
 
Statistical analyses 
A-SAA, hs-CRP and co-variables were tested for normal distribution. Furthermore, all numerical co-
variables were tested for correlation among each other using the Pearson’s coefficient of correlation 
for normally distributed variables and the Spearman’s coefficient of correlation for skewed distributed 
variables. Baseline characteristics of subjects who developed type 2 diabetes and those who remained 
diabetes-free were compared using five different tests: i) Pearson’s chi-square test to test for 
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independence of categorical variables between groups, (ii) Fisher’s exact test to test for independence 
between groups with small sample sizes in categories, (iii) Student’s two sample t-test for normally 
distributed numerical variables with equal variances, (iv) Welch’s t-test for normally distributed 
numerical variables with unequal variances, and (v) the Mann-Whitney-U test for skewed distributed 
numerical variables. Multivariate linear and logistic regression analyses with various degrees of 
adjustment were performed. Interactions between A-SAA and sex as well as A-SAA and age were 
assessed by adding an interaction term to the multivariate models. Two-sided p-values that were 
below 0.05 were considered to be statistically significant. All statistical analyses were conducted 
using SAS (Version 9.2, SAS Institute, Cary, NC).  
 
 
3.1.2. Results 
Baseline characteristics stratified by incident type 2 diabetes status are provided in Table 2. Seven-
year cumulative incidence of type 2 diabetes was 11.1 % (n = 93). Circulating systemic A-SAA levels 
were significantly higher (i) in diabetic subjects (median of A-SAA levels 4.0 mg/l [IQR, 2.6-6.8]) 
than in non-diabetic subjects (3.4 mg/l, [IQR, 2.2-5.4]); p = 0.009), (ii) in women (median 3.9 mg/l 
[IQR, 2.6-6.1]) than in men (2.9 mg/l, [IQR, 2.0-4.7]); p < 0.0001), and (iii) in subjects between 65 
and 74 years of age (median 3.6 mg/l [IQR, 2.3-6.2]) than in subjects between 55 and 64 years of age 
(3.3 mg/l [IQR, 2.2-5.0]; p = 0.03).  All co-variables were correlated with each other with r < 0.5 
except for hs-CRP and A-SAA (r = 0.50, Table 1 Appendix). 
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Table 2. Baseline characteristics of the study participants stratified by incident type 2 diabetes 
status. 
  No diabetes 
Incident  
type 2 diabetes 
p 
N (%) 743 (88.9) 93 (11.1)   
Age (years) 63.02 (5.35) 65.16 (5.06) 0,0002 
Male (%) 48,3 63,4 0.006 
BMI (kg/m²) 27.84 (3.97) 30.30 (3.41) <.0001 
Never smoking/ 54.1/ 39.8/ 
0,03 former smoker/ 34.9/ 45.2/ 
current smoker (%) 11 15,1 
Alcohol intake (g/day)* 8.57 (0.89-23.14) 11.43 (1.57-26.14) 0,42 
Vigorous/ 20.1/ 16.1/ 
0.62 
moderate/ 27.9/ 28.0/ 
mild/ 17.4/ 15.1/ 
no leisure time physical activity (%) 34,7 40,9 
No educational degree/ 1.4/ 2.2/ 
0.38 
Lower secondary educational degree/ 64.1/ 68.8/ 
Secondary educational degree/ 21.1/ 14.0/ 
High secondary educational degree/ 4.7/ 7.5/ 
University degree (%) 8.8 7.5 
Systolic blood pressure (mmHg) 133 (19) 138 (19) 0.009 
Lipids       
          Non-HDL cholesterol (mmol/l) 4.78 (1.07) 4.90 (1.16) 0.35 
          Triglycerides (mmol/l)* 1.22 (0.89-1.73) 1.55 (1.21-2.02) <.0001 
Glucose homeostasis       
          Fasting glucose (mg/dl) 97.78 (8.75) 106.40 (10.49) <.0001 
          Fasting insulin (μU/ml)* 9.3 (6.75-13.20) 13.5 (10.05-21.15) <.0001 
          HbA1c (%)* 5.6 (5.4-5.8) 5.8 (5.6-6.0) <.0001 
          HOMA-IR 3.03 (4.01) 4.88 (4.92) <.0001 
          2h glucose (mg/dl)* 106 (89-126) 146 (117-176) <.0001 
Inflammatory markers       
          A-SAA (mg/l)* 3.40 (2.20-5.40) 4.00 (2.60-6.80) 0.009 
          hs-CRP (mg/l)* 1.39 (0.72-2.75) 2.52 (1.25-3.78) <.0001 
At least one parent diabetic/ 21.9/ 36.6/ 
0.004 no parent diabetic/ 59.9/ 44.1/ 
no information (%) 18.2 19.4 
 
Data with normal and skewed distribution (indicated by *) are given as mean (SD) and median 
(interquartile range) of the variables. P-values: Pearson’s chi-square test, Fisher’s exact test, Student’s 
two sample t-test, Welch’s t-test, and Mann-Whitney-U test. P-values printed in bold letters indicate a 
statistically significant difference.   
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Table 3 presents the association between baseline A-SAA levels and incident type 2 diabetes. A-SAA 
concentrations were significantly associated with the development of type 2 diabetes during the 
seven-year follow-up period. The OR (adjusted for age and sex, model 1) for a 1-SD (4.16 mg/l) 
increase in A-SAA was 1.28 [95% CI, 1.08-1.53], p = 0.005. The association remained statistically 
significant after adjustment for multiple co-variables including BMI (model 2) and further traditional 
risk factors (smoking, alcohol intake, physical activity, education, parental history of diabetes, non-
HDL cholesterol, fasting triglycerides, systolic blood pressure, model 3). To further evaluate the 
impact of body fat and body composition on the association between A-SAA levels and incident type 
2 diabetes BMI was replaced by WHR or, alternatively, body fat mass index, lean body mass index, 
and appendicular skeletal muscle mass index as proposed by Kyle [204, 205] in model 2 of the 
association analysis. These analyses yielded results similar to those displayed in Table 3 (Table 2 
Appendix). The effect estimates decreased and the association was attenuated after additional 
adjustment for baseline parameters of glucose metabolism (fasting glucose, fasting insulin, HbA1c 
and 2h-glucose, model 4). Sensitivity analyses demonstrated that the attenuation was attributable 
mostly to adjustment for 2h-glucose (model 3 + fasting glucose + fasting insulin: OR = 1.25 [95 % CI, 
1.03-1.52], p = 0.02; model 3 + HbA1c: OR = 1.21 [95 % CI, 1.01-1.46], p = 0.04; model 3 + 2h-
glucose: OR = 1.17 [95 % CI, 0.97-1.42], p = 0.11). In multivariable linear regression analyses the 
association between baseline levels of A-SAA and ln-transformed levels of 2h-glucose at follow-up 
was statistically significant in all four models (model 1: ß = 0.01, se(ß) = 0.003, p < 0.0001, model 2: 
ß = 0.008, se(ß) = 0.003, p = 0.0009, model 3: ß = 0.007, se(ß) = 0.002, p = 0.004, model 4: ß = 0.006, 
se(ß) = 0.002, p = 0.008, N = 803). 
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Table 3. Results of the overall and age-stratified associations between circulating concentrations 
of A-SAA and incident type 2 diabetes according to four different models of co-variables 
adjustment. 
Stratum 
(T2D/nondiabetic) 
 
all (93/743) 
 
55-64 years (43/457) 
 
65-74 years (50/286) 
 
 
Covariables OR (95% CI) P OR (95% CI) P OR (95% CI) P 
1 age + sex 1.28 [1.08; 1.53] 0.005 1.48 [1.17; 1.88] 0.001 1.21 [0.94; 1.55] 0.14 
2 model 1 + BMI 1.25 [1.05; 1.50] 0.01 1.40 [1.09; 1.79] 0.009 1.21 [0.94; 1.09] 0.15 
3 
model 2 + 
traditional risk 
factors* 1.22 [1.02; 1.46] 0.03 1.38 [1.06; 1.80] 0.02 1.15 [0.88; 1.51] 0.3 
4 
model 3 + 
glucose related 
parameters** 1.16 [0.95; 1.42] 0.16 1.24 [0.85; 1.80] 0.27 1.07 [0.80; 1.43] 0.67 
 
* traditional risk factors are smoking, physical activity, alcohol consumption, education, parental 
history of diabetes, non-HDL cholesterol, fasting triglycerides, and systolic blood pressure 
**glucose related parameters include fasting glucose, fasting insulin, HbA1c, and 2h-glucose 
Odds ratios (95% CI) are given for a 1-SD increase of A-SAA concentrations (4.16 mg/l for all, 3.34 
mg/l for younger, and 5.11 mg/l for older age stratum). Smoking is coded in three classes (never, 
former and current smoker). Physical activity is coded in four classes (none, mild = irregularly 1h per 
week, moderate = regularly 1 h per week, and vigorous= regularly 2h or more per week). Education is 
coded in five classes based on the highest degree of education. Parental history is coded in three 
classes (at least one parent has/had T2D, none of the parents has/had T2D, no information on parental 
history). 
 
 
 
Stratification by sex showed that effect sizes in general were stronger in women than in men but the 
multiplicative interaction term between sex and A-SAA was not statistically significant (p > 0.1). 
Replacement of BMI by WHR, body fat mass index, lean fat mass index, or appendicular skeletal 
muscle mass index also did not indicate a statistically significant sex effect. However, the 
multiplicative interaction term between the metric age variable and A-SAA was borderline significant 
regarding the outcome of incident type 2 diabetes (p-value for interaction adjusted for age and sex = 
0.047). Therefore, we also calculated age-stratified ORs using 10-year age strata (Table 3). Stratified 
analyses showed that the A-SAA variability was higher in the age stratum 65-74 years (SD for age 
stratum 55-64 years = 3.34 mg/l, SD for age stratum 65-74 years = 5.11 mg/l). The association 
between A-SAA and incident type 2 diabetes was only significant in younger subjects (OR for the age 
group 55-64 years adjusted for age and sex = 1.48 [95 % CI, 1.17-1.88], p = 0.001; OR for the age 
group 65-74 years adjusted for age and sex=1.21 [95 % CI, 0.94-1.55]; p = 0.14). Furthermore, 
sensitivity analyses demonstrated, that for the age group 55-64 years the effect was mostly attenuated 
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by adjustment for HbA1c and not 2h-glucose (model 3 + fasting glucose + fasting insulin: OR = 1.44 
[95% CI, 1.07-1.92], p = 0.03; model 3 + HbA1c: OR = 1.26 [95 % CI, 0.93-1.70], p = 0.14, model 3 
+ 2h-glucose: OR = 1.37 [95 % CI, 1.00-1.86], p = 0.05], whereas for the age group 65-74 years, it 
was mainly affected by adjustment for 2h-glucose (model 3 + fasting glucose + fasting insulin: OR = 
1.17 [95 % CI, 0.89-1.55], p = 0.31; model 3 + HbA1c: OR = 1.18 [95 % CI, 0.90-1.56], p = 0.23, 
model 3 + 2h-glucose: OR = 1.06 [95 % CI, 0.80-1.41], p = 0.69). 
The association between baseline levels of hs-CRP and incident type 2 diabetes was analyzed 
similarly to the baseline levels of A-SAA (Figure 6). The hs-CRP effect estimate was somewhat 
larger than the effect size for A-SAA when adjusted only for age and sex (OR = 1.39 [95 % CI, 1.10-
1.68], p = 0.0006), but similar after full adjustment for all co-variables (OR = 1.13 [95 % CI, 0.88; 
1.45], p = 0.34). No evidence for an age-specific effect was found for hs-CRP (p-value for interaction 
> 0.1).  
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Figure 6: OR and 95 % CI for the association between baseline levels of A-SAA and hs-CRP with 
incident type 2 diabetes. 
*Traditional risk factors include smoking, alcohol intake, physical activity, education, parental history 
of diabetes, non-HDL cholesterol, fasting triglycerides, and systolic blood pressure. 
** Parameters of glucose metabolism are baseline levels of fasting glucose and fasting insulin, 
HbA1c, and 2h-glucose. 
Smoking is coded in three classes (never, former and current smoker). Physical activity is coded in 
four classes (none, mild = irregularly 1h per week, moderate = regularly 1 h per week, and vigorous = 
regularly 2h or more per week). Education is coded in five classes based on the highest degree of 
education. Parental history is coded in three classes (at least one parent has/ had type 2 diabetes, none 
of the parents has/ had type 2 diabetes, no information on parental history). 
 
 
 
Sensitivity analyses were conducted to assess the impact of menopausal status, hormone replacement 
therapy, intake of aspirin, and liver disease in the association between levels of A-SAA and incident 
type 2 diabetes by adjusting for these variables, but all analyses yielded very similar results as those 
displayed in Table  3 (Table 3 Appendix). 
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3.1.3. Discussion 
In this study a significant association between elevated systemic levels of A-SAA and the 
development of type 2 diabetes was observed in a large population-based cohort with long-term 
follow-up. This finding extends observations from earlier cross-sectional studies that reported a 
positive association between systemic A-SAA concentrations and prevalent type 2 diabetes and 
related traits [147-149]. Furthermore, the study showed that the association between A-SAA and 
incident type 2 diabetes was independent of various established type 2 diabetes risk factors, most of 
which were correlated with A-SAA cross-sectionally in this study. These risk factors include age and 
sex and the traditional type 2 diabetes risk factors smoking, alcohol, physical activity, education and 
parental history of diabetes, total cholesterol, fasting triglycerides and systolic blood pressure. The 
association of A-SAA with incident type 2 diabetes was also independent of BMI or, alternatively, 
other measures of body fat and body composition such as WHR, body fat mass index and lean body 
mass index. This is particularly notable since concentrations of A-SAA are known to be elevated in 
obese subjects [120] and since the pro-inflammatory cytokines and A-SAA inducers IL-6 and TNF-α 
as well as A-SAA itself were found to be partly expressed in adipose tissue [45, 46, 206]. 
Additionally, the administration of recombinant A-SAA in mice adipocytes results in a down-
regulation of genes that are critical for insulin sensitivity in the treated cells [207]. Our results suggest 
that apart from adipose tissue other metabolically critical sites, such as the liver, seem to be involved 
in the course of the disease. Furthermore, there was no evidence for a role of appendicular skeletal 
muscle mass index in the association between A-SAA and incident type 2 diabetes which makes 
confounding effects by myokines unlikely. 
 
Relationship between A-SAA, post-challenge hyperglycemia, and incident type 2 diabetes  
The difference in A-SAA levels between individuals with incident type 2 diabetes and study 
participants who remained diabetes-free was attenuated after adjustment for baseline parameters of 
glucose metabolism which indicate early impairments of glucose homeostasis. Sensitivity analyses 
showed that levels of 2h-glucose contributed most strongly to this attenuation. This suggests that 
elevated levels of A-SAA could be associated with early alterations in glucose control. Thus, elevated 
levels of circulating A-SAA might be a consequence of a pre-diabetes process, rather than a cause of 
it. Alternatively, post-challenge hyperglycemia might be an intermediate variable linking A-SAA to 
the development of type 2 diabetes. To further elucidate the question regarding the direction of 
causality, baseline levels of A-SAA and levels of 2h-glucose at follow-up were analyzed. These 
analyses yielded a significant association independent of baseline parameters of glucose metabolism 
which suggests an independent impact of circulating levels of A-SAA on glucose homeostasis and 
thus supports the hypothesis of post-challenge hyperglycemia as an intermediate variable. However, 
the analyses do not allow inferences on reverse causality between levels of 2-glucose and A-SAA. 
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Consequently, it cannot be ruled out that the relationship between A-SAA and 2h-glucose might be 
bi-directional.  
 
Comparison of the data with the literature 
In accordance with a previous study [149], our study demonstrated that A-SAA concentrations were 
higher in women than in men but the estimates for A-SAA concentrations regarding risk of incident 
type 2 diabetes did not differ significantly between men and women, as had been suggested for hs-
CRP [97]. 
The finding of the present study differed from those of the Sandy Lake Health and Diabetes Project 
[151]. This study had an even broader age range (10-79 years), similar co-variables and a similar sex 
distribution but did not observe a significant association between SAA and incident type 2 diabetes, 
although effect estimates pointed into the same direction. The 10-year cumulative incidence was high 
(17.5%), but fewer subjects (n=492) were analyzed. Thus, results may differ due to a lower statistical 
power of the Sandy Lake Health and Diabetes Project. In addition, the study was conducted in 
Aboriginal Canadians and ethnic factors might also be responsible for the different results.  
 
The association between A-SAA and incident type 2 diabetes is possibly modulated by age 
In this study, the association between levels of A-SAA and incident type 2 diabetes seemed to be age-
dependent. Stratified analyses showed that the variability of A-SAA levels was higher in older 
subjects and the association of A-SAA with incident type 2 diabetes was only significant in younger 
subjects. In the age group 55-64 years the effect was attenuated mainly by adjustment for HbA1c but 
not levels of 2h-glucose. This suggests that elevated levels of A-SAA may play a more important role 
in the development of type 2 diabetes in younger subjects and that the pathogenic mechanisms may 
differ in an age-dependent manner. Also, there was no evidence of an influence of hormonal changes 
during menopause or hormone replacement therapy in women on the observed age effect. Notably, 
the age-dependent differences were evident in our study population with elderly participants of a 
relatively small age range (55-74 years). It might be even more pronounced in study populations with 
younger participants and broader age ranges. However, we only found an effect modification by age 
for A-SAA, but not for hs-CRP. Therefore, further research is required to confirm and clarify the role 
of age in the context of innate immunity and the development of type 2 diabetes.   
 
A-SAA versus hs-CRP and incident type 2 diabetes 
To compare the strength of the putative association between levels of A-SAA and incident type 2 
diabetes with that of another acute-phase protein, also levels of hs-CRP as the best established 
inflammatory marker were analyzed. Effect estimates for hs-CRP were initially higher than for A-
SAA, but were attenuated more strongly when adjusting for the same co-variables. After full 
adjustment for all co-variables effect sizes for A-SAA and hs-CRP were similar. 
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Limitations and strengths of the study 
Several potential limitations of the study have to be mentioned. Firstly, due to the restrictions in 
laboratory methods analyses were confined to the A-SAA isoforms and did not capture the 
constitutively expressed C-SAA isoform which, however, responds only moderately to inflammatory 
stimuli. Secondly, only one A-SAA measurement was available, although multiple measurements for 
the determination of inflammatory proteins are preferred [208]. And third, this study did not assess the 
possible influence of energy intake or liver steatosis on the association between levels of A-SAA and 
incident type 2 diabetes. Strengths of this study are its prospective design, the well-defined study 
population sample and the definition of type 2 diabetes based on validated diagnosis and OGTT at 
both time points. In addition, the present study accounted for baseline parameters of glucose 
metabolism and thus early impairments of glucose homeostasis. 
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3.2. Genome-wide association study identifies two novel regions at 11p15.5-p13 and 1p31 with 
major impact on acute-phase serum amyloid A 
 
This chapter has been published in Marzi, C. et al., Genome-Wide Association Study Identifies Two 
Novel Regions at 11p15.5-p13 and 1p31 with Major Impact on Acute-Phase Serum Amyloid A, 
PloS Genetics PLoS Genet. 2010 Nov 18;6(11):e1001213. 
 
3.2.1. Materials and Methods 
Participating studies 
This meta-analysis combined data from four genome-wide scans: the KORA S4 study, the 
Ludwigshafen Risk and Cardiovascular Health study (LURIC), the UK Adult Twin Register 
(TwinsUK) and a self-contained population from Eastern Germany (Sorbs). Approval was obtained 
by each of the local Ethic Committees for all studies and written informed consent was given by all 
study participants. In total, the meta-analysis included 4,212 individuals (1,928 males, 2,284 females) 
of European ancestry with measured baseline A-SAA concentrations. For validation analyses, data of 
2,136 participants of the KORA S4 sample, which were not included in the meta-analysis were used 
(Text 1 Appendix). Sample sizes and characteristics of the study participants of the four genome-wide 
scans and the validation sample are displayed in Table 4 Appendix. 
 
Measurement of A-SAA concentrations 
In all four studies, study participants were fasting and EDTA plasma samples were analyzed by 
immunonephelometry on a BN II device from Siemens, Germany, and well-validated automated 
microparticle capture enzyme immunoassays [148, 209]. The inter-assay coefficients of variation 
were below 7 % in all four studies. 
 
Genome-wide genotyping and imputation 
For genotyping different platforms as the Affymetrix 500K GeneChip array (Sorbs), Affymetrix 6.0 
GeneChip array (KORA S4, LURIC, Sorbs), Illumina HumanHap300 BeadChip (317K) (TwinsUK) 
and Illumina Human 610K BeadChip (TwinsUK) were used. Quality control before imputation was 
undertaken in each study separately. Detailed information on genotyping and imputation is reported in 
Table 5 Appendix. Imputation based on the HapMap Phase 2 CEU population was performed using 
IMPUTE [174] in all studies. After imputation all genotype data had to meet the following quality 
criteria: a MAF ≥ 0.01, a call rate per SNP ≥ 0.9, and r2.hat metrics ≥ 0.40 for imputed SNPs. In total, 
2,593,456 genotyped or imputed autosomal SNPs were analyzed in the meta-analysis. 
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For validation and comparison of genotyping platforms, 27 of the SNPs with the lowest p-values in 
the association analysis were selected. Genotyping of these SNPs was performed with the 
MassARRAY system using the iPLEX technology (Sequenom, San Diego, CA) in the KORA S4 
study. The allele-dependent primer extension products were loaded onto one 384-element chip using a 
nanoliter pipetting system (SpectroCHIP, Spectro-POINT Spotter; Sequenom), and the samples were 
analyzed by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (Bruker 
Daltonik, Leipzig, Germany). The resulting mass spectra were analyzed for peak identification via the 
SpectroTYPER RT 3.4 software (Sequenom). To control for reproducibility, 9.8 % of the samples 
was genotyped in duplicate with a discordance rate of less than 0.5 %. 
 
Genome-wide association analyses and meta-analysis 
In each study, linear regression models for all available SNPs were calculated on ln-transformed A-
SAA levels in mg/l. The genetic effect was assumed to be additive. Adjustment was made for age, 
gender, BMI, and study specific covariates, i.e. the Friesinger Score in the LURIC population [210] 
and a genotyping batch variable in the TwinsUK population. Additionally, this analysis was 
undertaken stratified by gender. The genome-wide scans were calculated with the analysis software 
SNPTEST (http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html) (KORA S4, LURIC) 
QUICKTEST (http://toby.freeshell.org/software/quicktest.shtml) (Sorbs) and Merlin 
(http://www.sph.umich.edu/csg/abecasis/Merlin/) (TwinsUK). 
The results of all four genome-wide scans were meta-analyzed using a fixed-effects model applying 
inverse variance weighting with the METAL software (www.sph.umich.edu/csg/abecasis/metal). 
Study specific results were corrected for population stratification using the genomic control method. 
For the overall meta-analysis, the inflation factor was 1.009. No further correction was applied. 
P-values below the threshold of p = 5×10
−8
, which corresponds to a Bonferroni correction for the 
estimated number of one million tests for independent common variants in the human genome of 
European individuals [181], were considered to be significant. 
As a measure for between study heterogeneity I
2
 was calculated [187]. Deviations from Hardy-
Weinberg-Equilibrium were tested for all identified SNPs by means of the exact Hardy Weinberg test. 
For the calculation of explained variances, the multiple R
2
 value of the covariate model was 
subtracted from those of the full model including covariates and top hits of the loci in every single 
study and the weighted mean (KORA S4, LURIC, and the Sorbs) was assessed. Adjacent regions 
were tested for independency by analyzing the significance of their top SNPs in a joint model. 
 
Accession numbers 
The OMIM (http://www.ncbi.nlm.nih.gov/omim) accession numbers for genes mentioned in this 
article are 104750 for SAA1, 607521 for HPS5, 189972 for GTF2H1, 150000 for LDHA, 150150 for 
LDHC, 601007 for LEPR, and 606051 for SERGEF. 
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3.2.2. Results 
In this meta-analysis of four genome-wide scans 106 SNPs distributed across two regions showed 
genome-wide significant associations with p-values below the threshold of 5×10
−8
 (Figure 7, Table 6 
Appendix). Table 4 shows study specific results for the top hits within the two regions and three 
identified subregions (see below) of the meta-analysis as well as an additional region for men in the 
gender stratified analysis. Genotypic mean levels are provided in Table 7 Appendix. Results of the 
single genome-wide studies were consistent across all four studies regarding the direction and 
magnitude of the effects. In addition, results were consistent between different genotyping 
technologies (Table 8 Appendix). No deviations from the Hardy-Weinberg-Equilibrium were 
observed. The variable of inter-study heterogeneity (I
2
) showed homogeneity at the 1p31 locus. At the 
11p15.5-p13 locus we observed I
2
 values that indicated a more distinct heterogeneity. This reflects the 
relatively large and varying beta values and differences in the MAF (Table 6 Appendix). However, 
taking into account that this locus was clearly significantly associated with A-SAA in all studies 
included in the meta-analysis, results of the meta-analysis are reported based on a fixed effect model. 
 
 
 
Figure 7: Manhattan plot and quantile-quantile plot of the results of the meta-analysis on baseline 
A-SAA levels.  
The Manhattan plot on the left hand side displays all analyzed SNPs with their calculated p-values (p-
values below the threshold of genome-wide significance are colored red). The quantile-quantile plot 
on the right hand side points out the observed significant associations beyond those expected by 
chance. 
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Table 4. Study-specific results for the hits within the regions/ subregions. 
chr 
SNP 
region/subregion study 
effect 
allele 
other 
allele imp 
Effect 
allele 
freq n beta se(beta) p 
11 rs4150642 KORA S4 G C I 0.200 1785 0.529 0.032 1.92E-58 
 11p15.5-p13 LURIC G C I 0.212 961 0.569 0.075 6.51E-14 
 region Sorbs G C I 0.212 883 0.524 0.042 1.22E-32 
  TwinsUK G C I 0.109 550 0.358 0.050 8.27E-13 
  combined G C -  0.193 4179 0.501 0.022 3.20E-111 
  validation  G C G 0.217 2082 0.473 0.029 7.41E-58 
11 rs4638289 KORA S4 A T I 0.347 1785 0.323 0.027 4.95E-31 
 SAA1 LURIC A T I 0.358 961 0.235 0.063 2.17E-04 
 subregion Sorbs A T I 0.320 883 0.405 0.044 1.71E-19 
  TwinsUK A T I 0.214 514 0.206 0.041 5.70E-07 
  combined A T -  0.327 4143 0.305 0.020 2.77E-53 
  validation  A T G 0.332 2091 0.292 0.025 1.61E-30 
11 rs4353250 KORA S4 T C I 0.339 1785 0.278 0.027 1.06E-24 
 HPS5/GTF2H1  LURIC T C I 0.351 961 0.364 0.060 2.21E-09 
 subregion Sorbs T C I 0.413 883 0.310 0.035 3.21E-18 
  TwinsUK T C I 0.256 577 0.188 0.035 9.01E-08 
  combined T C  - 0.346 4206 0.272 0.018 1.68E-51 
  validation  T C G 0.352 2125 0.345 0.025 5.82E-42 
11 rs2896526 KORA S4 G A I 0.177 1785 0.265 0.033 3.99E-15 
 LDHA/LDHC  LURIC G A I 0.181 961 0.271 0.079 6.58E-04 
 subregion Sorbs G A I 0.163 883 0.226 0.048 3.00E-06 
  TwinsUK G A I 0.156 582 0.123 0.042 3.27E-03 
  combined G A  - 0.172 4211 0.221 0.023 4.12E-22 
  validation  G A G 0.187 2097 0.216 0.031 8.18E-12 
1 rs12753193 KORA S4 A G I 0.613 1785 0.103 0.027 1.94E-04 
 1p31 (LEPR) LURIC A G I 0.601 961 0.094 0.064 1.44E-01 
 region Sorbs A G I 0.599 883 0.177 0.038 4.15E-06 
  TwinsUK A G G 0.628 583 0.133 0.033 5.86E-05 
  combined A G  - 0.609 4212 0.125 0.018 1.22E-11 
  validation  A G G 0.606 2127 0.085 0.025 8.60E-04 
11 rs549485 KORA S4 T C G 0.335 871 0.155 0.040 9.77E-05 
 males only LURIC T C G 0.368 691 0.105 0.076 1.17E-01 
 11p14 (SERGEF) Sorbs T C G 0.309 361 0.272 0.144 3.18E-05 
 region combined T C - 0.342 1923 0.173   0.031   2.76E-08 
  vlidation* C G G 0.349 1049 0.091 0.035 8.50E-03 
 
*In the validation analysis rs549485 was replaced by rs493767 (r²=0.961, 3rd lowest p-value within 
this region in the gender stratified meta-analysis) for technical reasons. 
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The first region (193.3 kb of length) resides at 11p15.5-p13 and includes SAA1 one of the structure 
genes of A-SAA. Within this region the strongest association was found for two highly correlated 
intronic polymorphisms of the general transcription factor 2 H1 (GTF2H1) gene, rs4150642 (p = 
3.20×10
−111
) and rs7103375 (p = 3.26×10
−111
) (Figure 8A). These two top hits show modest 
correlation (r 
2≤ 0.376) with other significantly associated SNPs within this region. When the structure 
of correlation and explained variances within the region were analyzed three mostly independent 
subregions were identified (Table 9 Appendix, Figure 8B – D). The first subregion encloses the 5′ end 
of SAA1 (Figure 8B) with strongest association for rs4638289 (p = 2.77×10
−53
). The other two 
subregions harbor the genes Hermansky-Pudlak Syndrome 5 (HPS5) and GTF2H1 (Figure 8C) and 
lactate dehydrogenase A and C (LDHA and LDHC) (Figure 8D) with strongest associations for 
rs4353250 (p = 1.68×10
−51
) and rs2896526 (p = 4.12×10
−22
), two intronic polymorphisms of HPS5 
and LDHA, respectively.  
The second region was detected at 1p31 (Figure 8E). All 38 significantly associated variants cluster 
around the 3′ end of the leptin receptor gene (LEPR). The SNP with the lowest p-value, rs12753193, 
(p = 1.22×10
−11
) is located downstream of LEPR. 
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Figure 8: Regional plots of the genetic susceptibility regions/ subregions. 
Regional plots present gene regions and block structures of the region at 11p15.5-p13 (A), the SAA1 
subregion (B), the HPS5/GTF2H1 subregion (C), the LDHA/LDHC subregion (D), and the region at 
1p31 (E) and picture the probability values of the significantly associated SNPs, the colour 
representing the degree of correlation with the top hit of the respective region/subregion.  
 
All associations were consistent in the KORA S4 validation analyses (Table 4 for the top hits, Table 
10 Appendix for all SNPs selected for validation). 
The entire regression model (including the top SNPs of the two genomic regions (rs4150642 and 
rs12753193), age, gender and BMI) explains 19.32 % of the total variation of A-SAA in our data. 
With an explained variance of 10.84 % for the top SNP (rs4150642) of the 11p15.5-p13 locus (5.57 % 
for rs4638289 of the SAA1 subregion, 5.34 % for rs4353250 of the HPS5/GTF2H1 subregion, and 
2.37 % for rs2896526 of the LDHA/LDHC subregion; Table 9 Appendix) and 0.93 % for the top SNP 
(rs12753193) of the 1p31 locus the identified genomic regions account for a major part of such 
variance. 
When the analysis was stratified by gender, one additional SNP (rs549485) located about 350 kb apart 
from the SAA1 subregion at 11p14 in the secretion regulating guanine nucleotide exchange factor 
(SERGEF) gene showed a borderline significant association with A-SAA levels in men (p = 
2.76×10
−8
) in the meta-analysis. In the validation analysis the association between two highly 
correlated SNPs within this region (rs493767 and rs550659, r
2
 = 0.961) and A-SAA levels was also 
borderline significant (p = 8.50×10
−3
 and p = 1.65×10
−2
, respectively). No significant differences 
between men and women were found within the regions identified in the overall meta-analysis (data 
not shown). 
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3.2.3. Discussion 
Genetic susceptibility loci for circulating levels of A-SAA 
Based on a meta-analysis of four genome-wide association studies including 4,212 participants of 
European descent two novel genetic susceptibility regions were identified to be associated with 
baseline A-SAA concentrations in this study. With 11.68 % explained variance in this data, which 
makes up 19.76 % of the total estimated heritability of 59 %, these two regions seem to have a major 
impact on baseline A-SAA concentrations.  
 
A-SAA susceptibility region 11p15.5-p13 
The region at 11p15.5-p13 accounts for most of the explained variance. Its SAA1 subregion contains 
part of a highly conserved region between the two bona fide acute-phase structure genes SAA1 and 
SAA2, which consist of at least 5 and 2 allelic variants, respectively [116, 127]. These two genes are 
concurrently induced during the acute-phase [116], and cluster within 18 kb of each other in a head to 
head arrangement [128]. This study is the first presenting the complex genetic architecture of A-SAA 
levels at this locus. In the identified region, there has been evidence of regulatory elements like 
C/EBPalpha and C/EBPbeta (http://genome.ucsc.edu), which are necessary for the full responsiveness 
to IL-1β and IL-6 either alone or in combination [116]. This finding underlines the high functional 
potential for this region. 
The adjacent GTF2H1 is a basal transcription factor involved in nucleotide excision repair of DNA 
and RNA transcription by RNA polymerase II [211]. HPS5 encodes a protein, which is probably 
involved in organelle biogenesis associated with melanosomes and platelet dense granule, its 
mutations lead to a homonymous clinical entity [212]. And LDHA and LDHC, which are expressed in 
muscle tissue and in testes, respectively, encode for lactate dehydrogenase, an enzyme that catalyzes 
the interconversion of lactate and pyruvate [213]. 
Variants of the GTF2H1 gene have been recently found to be associated with lung cancer in a Chinese 
population [214]. Furthermore, it was demonstrated that LDHA is involved in tumour genecity and its 
reduction causes bioenergetic and oxidative stress leading to cell death [215-217]. Finally, 
Kosolowski et al. [218] found LDHC to be expressed in several types of tumour cell lines. It is 
thought, that recurrent or persistent chronic inflammation may play a role in carcinogenesis by 
causing DNA damage, inciting tissue reparative proliferation and/ or by creating an environment that 
is enriched with tumour-promoting cytokines and growth factors [146]. Furthermore, SAA synthesis 
has been found in human carcinoma metastases and cancer cell lines [119]. 
As the approach taken in this study is observational in nature it is not possible to draw causal 
inferences. For that reason, it could be possible that not genes, but small regulatory elements may be 
responsible for the findings. This is most likely the case as the identified region contains one structure 
gene and the adjacent region. In any case, the major impact on baseline A-SAA concentrations 
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demonstrates a key role of the 11p15.5-p13 region in the regulation of inflammation. Therefore, the 
identification of causal variants and their impact on diseases related to elevated baseline A-SAA 
concentrations represent promising targets for future functional and epidemiological studies. 
 
A-SAA susceptibility region 1p31 
The second region was found on chromosome 1p31, harboring the LEPR gene locus. Leptin, an 
important circulating signal for the regulation of body weight, was found to be correlated with SAA 
concentrations independently of BMI, and both were expressed in adipose tissue [219]. In the KORA 
F3 study (Text 1 Appendix) a moderate but significant correlation was found between circulating A-
SAA and leptin concentrations in blood in 181 participants with measurements of both proteins 
(Spearman correlation = 0.25, p < 0.001). So far it is unclear whether leptin influences SAA 
expression directly or via the leptin stimulated cytokines, IL-6 and TNF-α [219]. LEPR is a single 
transmembrane receptor of the cytokine receptor family most related to the gp130 signal-transducing 
component of the IL-6 receptor, the granulocyte colony-stimulating factor (GCSF) receptor, and the 
Leukaemia Inhibitory Factor (LIF) receptor, all of which are thought to play an essential role in the 
inflammatory process [220, 221]. Previous studies have provided evidence of an association of the 
LEPR gene locus with hs-CRP and fibrinogen [222-225], which were both correlated with A-SAA in 
the KORA S4 study (Text 1 Appendix) (hs-CRP: Spearman correlation = 0.58, p < 0.001, and 
fibrinogen: Spearman correlation = 0.31, p < 0.001; N = 1734). The finding gives confirmative 
evidence of the importance of the LEPR gene locus for inflammatory processes and the close 
relationship between leptin, A-SAA, hs-CRP and fibrinogen. 
 
Gender specific finding 
Furthermore, in the gender stratified analysis one region containing SERGEF was identified to be 
presumably associated with A-SAA in men. The adjacency of this identified region to the SAA gene 
family suggests that regulatory elements may be responsible for this signal. However, the association 
with A-SAA levels was only borderline significant in this study and therefore awaits replication. 
 
Limitations and strengths 
Two limitations of the study have to be mentioned. Firstly, like in the first study of this doctoral thesis 
due to the restrictions in laboratory methods analyses were confined to the A-SAA isoforms and did 
not capture the constitutively expressed C-SAA isoform which might also be of interest, especially 
when analyzing baseline SAA levels. Secondly, the number of studies with genome-wide data and 
measured A-SAA levels was limited compared to other genome-wide association studies. 
Nevertheless, the study had enough power to detect two novel genetic susceptibility regions for 
circulating A-SAA levels explaining 19.76 % of the total estimated heritability already. Furthermore, 
results were consistent across all four studies and within different genotyping platforms, the regions 
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are biologically highly plausible, and the results may contribute to future research on the regulation of 
inflammatory response and its role in related clinical entities. 
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3.3. Mendelian Randomization study on genetic susceptibility loci for A-SAA and type 2 
diabetes 
 
3.3.1. Materials and Methods  
The Mendelian Randomization study was conducted within the framework of a DIAGRAM meta-
analysis of eight GWAs on type 2 diabetes by Voight, B. et al., 2010 [39]. DIAGRAM is a large 
consortium which combines the efforts of about 40 scientific institutions working on the genetics of 
type 2 diabetes, particularly, in samples of European descent. The association between genetic 
variants which predispose to levels of A-SAA and type 2 diabetes was extracted from the results of 
this DIAGRAM meta-analysis. The study population and the statistical analysis are described in detail 
in this study [39] and are only summarized here. 
 
Study population of the published DIAGRAM meta-analysis 
The meta-analysis combined results of eight genome-wide scans comprising 8,130 type 2 diabetes 
cases and 38,987 controls of European descent: DGDG (Diabetes Gene Discovery Group), deCODE, 
DGI (Diabetes Genetics Initiative), Rotterdam, EUROSPAN (European Special Population Network), 
FUSION (Finland-United States Investigation of NIDDM Genetics), KORAgen (Cooperative Health 
Research in the region of Augsburg, Southern Germany) and WTCCC/ UKT2D (Welcome Trust Case 
Control Consortium/ United Kingdom Type 2 Diabetes Genetics Consortium).  
 
Statistical analysis of the published DIAGRAM meta-analysis 
Less than 1,000 SNPs, where the allele frequencies were < 0.40 in at least one study and > 0.60 in 
others, were excluded to minimize possible difficulties due to mislabeled alleles. Genomic control 
correction of autosomal data from each individual study (separately for directly genotyped and for 
imputed data) was performed by inflating the standard error of the estimated effect so the significance 
of the SNP matched that of the genomic control value. The overall genomic control inflation factor 
was estimated to be 1.074 for ≥ 17,000 effective total samples indicating low population stratification. 
The genome-wide association analysis in the individual studies was conducted using an additive 
model, different covariates including age, sex, BMI, study center and/or birth province, and different 
analysis software as described in the online supplement of the DIAGRAM study [39]. Association 
data of the individual studies comprising 2,426,886 imputed and genotyped autosomal SNPs were 
combined in a meta-analysis using a fixed effect model and the inverse variance-weighted approach. 
Heterogeneity between study results was assessed by calculating I².  
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Genetic susceptibility regions for the Mendelian Randomization study 
For the Mendelian Randomization study, the SNPs with the smallest p-values of the two A-SAA 
susceptibility regions as well as the SNPs with the smallest p-value of each subregion which had been 
identified in the second study of this doctoral thesis were selected.  
 
Power calculation for the Mendelian Randomization study 
A power calculation was conducted to investigate whether the power to detect a significant 
association between the selected A-SAA loci and type 2 diabetes was sufficient. Therefore, effect 
estimates for the associations of the five selected SNPs and type 2 diabetes were calculated by 
combining results of the two studies presented prior to this study in the present doctoral thesis as 
following: the beta value of the meta-analysis of GWAS for the KORA study was divided by the 
standard deviation of ln-transformed A-SAA levels (0.66 mg/l) and multiplied by the natural 
logarithm of the OR for 1-SD increase of ln-transformed A-SAA levels in type 2 diabetes risk 
adjusted for age and sex (OR = 1.42, ln(OR) = 0.35). The result was subsequently raised to the power 
of e. To assess the power of the Mendelian Ranodmization study given the calculated combined effect 
estimates, allele frequencies as reported in the meta-analysis of genome-wide scans on levels of A-
SAA for the KORA study, and an additive genetic model, a power calculation was performed using 
Genetic Power Calculator by S. Purcell and P. Sham, 2001-2009 [226]. The effective sample size was 
calculated in the DIAGRAM meta-analysis to be 21,063 [39]. Diabetes prevalence was assumed to be 
8.1 % [13] and the threshold of significance was considered to be 0.05. 
 
 
3.3.2. Results 
Results of the DIAGRAM association analyses between the five selected SNPs and type 2 diabetes 
adjusted for age and sex are presented in Table 5. There was no significant association between any of 
the selected A-SAA susceptibility loci and type 2 diabetes.  
Table 6 shows the combined effect estimates for the association between the five selected SNPs and 
type 2 diabetes based on the results of the two previous studies of this doctoral thesis (beta values of 
the meta-analysis of GWAS on A-SAA levels and ORs for a 1-SD increase of ln-transformed A-SAA 
levels adjusted for age and sex of the prospective cohort study on A-SAA levels and incident type 2 
diabetes) as well as the power to detect a significant association between the five selected SNPs and 
type 2 diabetes.  
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Table 5. Results of the association analysis between five selected A-SAA susceptibility SNPs and 
type 2 diabetes in the DIAGRAM consortium (8,130 type 2 diabetic cases, 38,987 non-diabetic 
controls). 
SNP Chr 
Region/             
subregion Study* 
Effect 
allele 
Other 
allele OR [95% CI] p-value 
rs4638289 11 SAA1 +-+++--+ A T 1.04 [0.99-1.09] 0.163 
rs2896526 11 LDHA/LDHC +-+++-++ G A 0.98 [0.93-1.04] 0.569 
rs4150642 11 11p15.5-p13 --++-++- G C  0.99 [0.94-1.06] 0.854 
rs4353250 11 HPS5/GTF2H1 --++-+++ T C 1.00 [0.96-1.05] 0.906 
rs12753193 1 1p31 (LEPR) +++--+-- A G 1.00 [0.96-1.04] 0.932 
 
(+) = SNP was analyzed in the study, (-) = SNP was not analyzed in the study. *The order of the 
studies is DGDG, deCode, DGI, Rotterdam, EUROSPAN, FUSION, KORAgen, and WTCCC/ 
UKT2D.  
 
 
Table 6. Effect estimates for the association between the selected SNPs and type 2 diabetes and 
the estimated power to detect these effect estimates in the DIAGRAM meta-analysis. 
    Study 1 Study 2 Combined  Power calculation  
  
Effect allele 
frequency Beta OR OR [95% CI] Power 
rs4638289 0.347 0.323 1.42 1.19 [1.12-1.24] 1 
rs2896526 0.177 0.265 1.42 1.15 [1.09-1.20] 1 
rs4150642 0.200 0.529 1.42 1.32 [1.24-1.37] 1 
rs4353250 0.339 0.278 1.42 1.16 [1.10-1.21] 1 
rs12753193 0.613 0.103 1.42 1.05 [1.00-1.10] 0.95 
ORs adjusted for age and sex were calculated for 1-SD of ln-transformed A-SAA levels. 
 
The power to detect a significant association between the five selected SNPs and type 2 diabetes was 
> 0.8 for all SNPs. Likewise, the number of cases needed to detect a significant association between 
the five selected SNPs and type 2 diabetes given a power of 0.8 was far below the effective sample 
size of 21,063 for all five selected SNPs (585, 972, 1536, 2340, and 12,554, respectively). Sensitivity 
analysis showed that also for an assumed OR of 1.22 for study 2 which corresponds to an OR for a 1-
SD increase of ln-transformed A-SAA levels adjusted for age, sex, BMI, smoking, alcohol intake, 
physical activity, education, parental history of diabetes, non-HDL cholesterol, fasting triglycerides, 
systolic blood pressure, fasting glucose, fasting insulin, HbA1c and 2h-glucose the power to detect a 
significant association between all selected SNPs and type 2 diabetes was > 0.8 (data not shown). 
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3.3.3. Discussion 
This Mendelian Randomization was designed to assess whether elevated levels of A-SAA are causally 
involved in the development of type 2 diabetes. However, in this Mendelian Randomization study 
conducted in 8,130 type 2 diabetes cases and 38,987 controls subjects of European descent no 
significant association between susceptibility loci for circulating levels of A-SAA and type 2 diabetes 
was found. There may be three possible explanations for this finding: (i) genetic confounding might 
have biased the association between the selected genetic variants and type 2 diabetes, (ii) the power to 
detect a significant association was not sufficient, and (iii) the selected SNPs that predispose to 
plasma levels of A-SAA do not increase type 2 diabetes risk.   
 
Genetic confounding 
The association between the A-SAA susceptibility loci and type 2 diabetes might have been biased by 
genetic confounding evoked by pleiotropic effects or population stratification.  
No evidence for pleiotropic effects had been found in electronic searches of Medline and PubMed, 
supplemented by hand searches of reference lists for the selected SNPs of the 11p15.5-p13 region. 
Therefore, although it is not possible to totally exclude pleiotropic effects they do not seem likely for 
the 11p15.5-p13 region. Contrary to the 11p15.5-p13 locus, the A-SAA susceptibility region at 1p31 
harboring the LEPR gene had been found to be associated with further intermediate phenotypes of 
type 2 diabetes, namely leptin, fibrinogen, and hs-CRP [222-225]. All studies report on the same risk 
allele for the intermediate phenotypes. However, the associations between these intermediate 
phenotypes and type 2 diabetes might be oppositional as higher levels of fibrinogen and hs-CRP have 
been  found to be associated with type 2 diabetes [95] whereas high levels of leptin have been found 
to be both, a risk factor and a protective factor for incident type 2 diabetes [227, 228]. Thus, the 
association between the 1p31 locus and type 2 diabetes might be biased by pleiotropic effects and the 
direction of this bias cannot be clearly determined.   
Furthermore, a negative finding might be prone to population stratification. This Mendelian 
Randomization study was accomplished within the framework of a meta-analysis of eight different 
studies. Participants of all studies were of European descent and study specific results were corrected 
for population stratification using the genomic control method in all individual studies. The overall 
inflation factor was close to 1 indication low population stratification.  
 
 
Power calculation 
Finally, the absence of association of the selected SNPs with type 2 diabetes could be due to low 
statistical power. A valid power calculation for Mendelian Randomization studies requires the robust 
evaluation of the association between the genetic variant and the intermediate phenotype as well as 
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the valid assessment of effect estimates between the intermediate phenotype and the disease. Being 
the first genome-wide scan for A-SAA susceptibility loci ascertainment bias known as “the winner’s 
curse” and thus an overestimation of the effect size for the gene-intermediate phenotype may be 
present in the meta-analysis of GWAS on circulating A-SAA levels. Yet, results were consistent 
across all studies and within different genotyping platforms. In addition, the effect estimates that were 
assessed in the validation sample of the meta-analysis of GWAS on A-SAA levels displayed only 
slight differences from those assessed in the KORA study and the meta-analysis. Furthermore, the 
findings of the prospective cohort study indicated a possible reverse causality between post-challenge 
hyperglycemia and levels of A-SAA in the A-SAA-incident type 2 diabetes association. In this case, 
effect estimates and thereby combined effect estimates and the power to detect a significant gene-
disease association might also be overestimated. However, sensitivity analyses using effect estimates 
adjusted for parameters of glucose metabolism in the power calculation for the association between 
A-SAA levels and type 2 diabetes still displayed a sufficient power to detect a significant association 
between all selected SNPs and type 2 diabetes. Finally, minor differences might arise out of different 
adjustments for covariates in the studies of the DIAGRAM meta-analysis as well as in the power 
calculation of this Mendelian Randomization study. Yet, altogether, power calculations showed that 
the power to detect a significant association between all selected SNPs of the 11p15.5-p13 was by far 
sufficiently high and the absence of a significant association between the selected SNPs and type 2 
diabetes due to low statistical power seems unlikely.  
 
To sum up, for reasons of potential pleiotropic effects, the 1p31 susceptibility region was not qualified 
for the Mendelian Randomization study. In contrast, for the 11p15.5-p13 region no pleiotropic effects 
had been reported. Furthermore, population stratification was low and also the power to detect a 
significant association with type 2 diabetes for the 11p15.5-p13 region was reasonably high. 
Therefore, for the 11p15.5-p13 region, the negative results of the study suggest that there are genetic 
mechanisms that determine levels of A-SAA without affecting type 2 diabetes risk. Thus, although a 
presumed causality driven by other genetic and/ or non-genetic mechanisms might still be possible, 
evidence for a causal implication of elevated levels of A-SAA into type 2 diabetes pathogenesis on 
the basis of the results of this Mendelian Randomization study cannot be provided.  
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4. Conclusions 
This chapter is partly extracted from the manuscripts Marci C. et al., Acute-phase serum amyloid A 
protein and its implication in the development of type 2 diabetes in the KORA S4/ F4 study, 
Diabetes Care, 2012 Dec 13, epub ahead of print, and Marzi, C. et al., Genome-Wide Association 
Study Identifies Two Novel Regions at 11p15.5-p13 and 1p31 with Major Impact on Acute-Phase 
Serum Amyloid A, PloS Genetics PLoS Genet. 2010 Nov 18;6(11):e1001213. 
Type 2 diabetes is an increasing public health problem and the identification of etiological risk factors 
is of ascending relevance for the prevention as well as the treatment of the disease. There had been 
emerging evidence from epidemiological, genetic and functional studies that subclinical inflammation 
is causally involved in the development of type 2 diabetes (chapter 1.2.1.). However, little was known 
about the inflammatory protein A-SAA, one of the key molecules in host defense, and its implication 
in type 2 diabetes pathogenesis. It had been shown in cross-sectional studies that elevated levels of A-
SAA are correlated with prevalent type 2 diabetes, and related metabolic traits (chapter 1.2.2.) but 
these studies do not allow inferences on cause and effect (chapter 1.3.1.). Causal inferences in 
epidemiological studies are difficult to assess because epidemiology is an observational science. One 
first indication for causality is a significant association between risk factor and disease in a 
prospective cohort study. These study type incorporates the time sequence between risk factor and 
disease, an essential prerequisite for causality (chapter 1.3.1). A prospective cohort study on 
circulating A-SAA levels and incident type 2 diabetes had previously been conducted in 492 
Aboriginal Canadians. However, in this study the association between levels of A-SAA and incident 
type 2 diabetes was not significant. This might be due to low statistical power. Furthermore, there 
might be ethnic differences, and thus, deductions on an implication of elevated levels of A-SAA in the 
development of type 2 diabetes in Western Europeans cannot be drawn on the basis of these findings. 
Therefore, a prospective cohort study was performed to analyze the association between circulating 
levels of A-SAA and the development of type 2 diabetes in Western Europeans (chapter 3.1.). In this 
study, A-SAA concentrations were measured in 836 initially non-diabetic elderly Western European 
subjects, 55-74 years of age, without clinically overt inflammation who participated in a seven-year 
follow-up examination including an OGTT. Results of the study provided novel evidence that 
elevated levels of A-SAA are present years before the manifestation of type 2 diabetes independent of 
a variety of other type 2 diabetes risk factors but not parameters related to glucose metabolism.  
As the next step, the causality in the association between levels of A-SAA and type 2 diabetes was to 
be assessed. Clinical trials and intervention studies my assess causality in an association by analyzing 
the difference between two groups with initially equal risk factor profiles after the interesting risk 
factor has been changed or eliminated in one of the two groups (chapter 1.3.1.). This concept has 
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recently been adapted in genetic epidemiology and named Mendelian Randomization study (chapter 
1.3.3.). Mendelian Randomization studies provide the opportunity to detect associations between 
genetic variants as proxies for intermediate phenotypes and a disease largely unbiased by potential 
environmentally modifying factors. Thereby, they might be particularly useful for the identification of 
causal risk factors for complex diseases characterized by multifactorial environmental contributions to 
pathogenic mechanisms such as type 2 diabetes (chapter 1.3.3.). 
The identification of genetic variants that determine biomarker levels is a prerequisite for a Mendelian 
Randomization study. Apart from this, in the case of A-SAA levels, it could also provide important 
clues to the immune response pathways involved in the regulation of A-SAA levels. This might also 
be of relevance for related clinical entities such as type 2 diabetes. Twin studies suggested a 
substantial genetic contribution of about 60 % to baseline A-SAA concentrations but in the past 
association analyses between genetic variants and A-SAA levels had been limited to allelic variants of 
the SAA genes and protein concentrations (chapter 1.2.2.). The second study of this doctoral thesis 
was the first whole genome approach to identify genetic variants that determine baseline A-SAA 
concentrations (chapter 3.2.). In a meta-analysis of four genome-wide scans (KORA S4, LURIC, 
TwinsUK, and Sorbs) the association between 2,593,456 genetic variants across the whole genome 
and circulating levels of A-SAA was analyzed in 4,212 participants of European descent. Two novel 
genetic susceptibility regions at chromosome 11p15.5-p13 and chromosome 1p31 were identified to 
be associated with baseline A-SAA concentrations. The findings demonstrated a major impact of the 
11p15.5-p13 region on the regulation of inflammation and suggested a close interplay between leptin, 
A-SAA, and other acute-phase proteins, as well as a larger role of the LEPR gene locus in 
inflammatory processes as it had been assumed in the past. Both loci are biologically highly plausible 
A-SAA susceptibility regions and might represent promising targets for future functional and 
epidemiological studies to elucidate the up-regulation of A-SAA and its differential contribution to 
related diseases.  
 
The Mendelian Randomization study was accomplished within the framework of a published meta-
analysis of eight GWAS (8,130 type 2 diabetic cases, 38,987 non-diabetic controls) on type 2 diabetes 
(chapter 2.3.). This meta-analysis was conducted by scientists of the DIAGRAM consortium, a 
consortium of about 40 research institutes working on the genetics of type 2 diabetes, mainly, in 
samples of European descent. For the Mendelian Randomization study, those SNPs with the lowest p-
values in each region/ subregion identified in the meta-analysis of GWAS on A-SAA levels were 
selected as proxies for the Mendelian Randomization study and the association results were extracted 
from the results of the DIAGRAM meta-analysis. For the 11p15.5-p13 region no pleiotropic effects 
had been reported. In contrast, for reasons of potential pleiotropic effects and thus genetic 
confounding, the 1p31 susceptibility region was not qualified for the Mendelian Randomization study. 
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In spite of a reasonably high power the association between the selected SNPs of the 11p15.5-p13 A-
SAA susceptibility region and type 2 diabetes was not statistically significant. This suggests that there 
are genetic mechanisms that raise plasma levels of A-SAA without translating into an increase in type 
2 diabetes risk. Thus, the Mendelian Randomization study could not provide evidence that elevated 
levels of A-SAA are causally involved in type 2 diabetes pathogenesis.  
 
However, a putative causality between elevated levels of A-SAA and type 2 diabetes driven by other 
genetic and/ or non-genetic mechanisms might still be present. One possibility to further investigate 
this subject might be animal studies with knockouts or transgenic overexpression of A-SAA. 
However, although SAA genes and proteins are highly conserved throughout the evolution of 
vertebrates and invertebrates there are substantial differences between humans and mice, e.g. 
concerning the functionality of SAA3 (chapter 1.2.2.). Furthermore, the manipulation of the genome 
might constitute too gross disturbances to allow a transfer of results from animal models to the 
complex and delicate human immune and metabolic system [96]. Thus, animal studies might 
corroborate or falsify the hypothesis of a causal implication of A-SAA levels in the development of 
type 2 diabetes, but firm conclusions on human type 2 diabetes pathogenesis may not be drawn on the 
basis of such studies.  
Another approach to investigate causality in the association between circulating A-SAA levels and 
type 2 diabetes are pharmacological or lifestyle and behavioral intervention studies in humans. 
However, pharmacological interventions need to target inflammatory pathways only and may not be 
interwoven into glucose metabolism to allow deductions on the direction of causation. Furthermore, 
this approach requires monoclonal antibodies for A-SAA proteins in order to avoid pleiotropic effects, 
which is hardly feasible in practical research. In lifestyle and behavioral intervention studies, at first 
glance, the reduction of weight and at least moderate physical activity might be of particular interest 
in this context as A-SAA is highly correlated with BMI and partly expressed in adipose and muscle 
tissues (chapter 1.2.2.). Yet, in the prospective study on levels of A-SAA and incident type 2 diabetes, 
effect estimates decreased only slightly when adjusting for BMI or, alternatively, other measures of 
obesity or body composition as well as appendicular skeletal muscle mass index. This implies an only 
moderate effect of intervention studies targeting adiposity and physical inactivity only via a reduction 
of A-SAA concentrations. Furthermore, results of the prospective study of circulating A-SAA levels 
and incident type 2 diabetes indicated that the relevance of high circulating levels of A-SAA in the 
pathogenesis of type 2 diabetes might be age-dependent. Just as well as a possible difference between 
men and women (chapter 1.2.1.) this age effect, once confirmed, needs to be taken into account in 
intervention studies. However, like in pharmacological intervention studies, pleiotropic effects make 
it hard to draw deductions on a causal implication of levels of A-SAA in type 2 diabetes pathogenesis 
also in lifestyle and behavioral intervention studies.  
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In the prospective cohort study, the association between levels of A-SAA and incident type 2 diabetes 
attenuated when adjusting for parameters of glucose metabolism, particularly 2h-glucose. In contrast, 
baseline levels of A-SAA were significantly associated with levels of 2h-glucose at the time of 
follow-up even after adjusting for baseline parameters of glucose metabolism (chapter 3.1.). This 
indicates that elevated levels of A-SAA contribute to post-challenge hyperglycemia suggesting a 
possible link with type 2 diabetes pathogenesis via elevated levels of 2h-glucose. However, also a 
possible reverse impact of high levels of 2h-glucose on circulating levels of A-SAA cannot be ruled 
out. Thus, the association between elevated levels of A-SAA and 2h-glucose might also be bi-
directional. Biologically, a mutual impact between A-SAA and 2h-glucose might reflect a positive 
feed-back loop in the context of endoplasmic reticulum stress, mitochondrial dysfunction, and 
subclinical inflammation making it difficult to distinguish between inflammatory and metabolic 
consequence and condition. Time-series studies as performed for other markers of subclinical 
inflammation [229] might further elucidate the relationship between levels of A-SAA, post-challenge 
hyperglycemia, and type 2 diabetes.  
To summarize, results of this doctoral thesis indicated that levels of A-SAA are elevated years before 
the manifestation of type 2 diabetes. Furthermore, two highly plausible genetic susceptibility loci for 
circulating A-SAA levels were identified. One of these loci was a suitable candidate for a genetic 
approach to assess the causality in the association between elevated levels of A-SAA and type 2 
diabetes. However, evidence that the association between A-SAA concentrations and type 2 diabetes 
is truly causal could not be provided using this genetic approach. The prospective cohort study of this 
doctoral thesis suggested that the relation between elevated levels of A-SAA, post-challenge 
hyperglycemia and type 2 diabetes might be mutual and of a more complex nature. Time-series 
studies are warranted to further clarify this relation.  
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5. Appendix 
Table 1 Appendix. Correlation matrix of co-variables 
  
A-
SAA 
Age BMI 
Alcohol 
intake 
Non- 
HDL 
TG SBP 
Fasting 
insulin 
HbA1c 
Fasting 
glucose 
2h-
glucose 
hs-
CRP 
A-SAA 1 0.1 0.19 -0.09 0.02 0.06 0.08 0.14 0.06 -0.01 0.13 0.5 
Age   1 0.09 -0.04 0.02 -0.01 0.17 0.03 0.15 0.05 0.19 0.15 
BMI     1 -0.02 0.08 0.22 0.12 0.48 0.03 0.23 0.27 0.32 
Alcohol 
intake 
        0.002 0.008 0.12 -0.06 -0.08 0.17 -0.04 -0.02 
Non-
HDL 
        1 0.46 0.08 0.07 0.05 0.05 0.05 0.07 
TG           1 0.19 0.36 0.05 0.2 0.22 0.19 
SBP             1 0.15 0.03 0.21 0.19 0.16 
Fasting 
insulin 
              1 0.05 0.31 0.29 0.23 
HbA1c                 1 0.2 0.14 0.11 
Fasting 
glucose 
                  1 0.31 0.09 
2h-
glucose 
                    1 0.21 
hs-CRP                       1 
 
Non-HDL = non-HDL cholesterol; TG = triglycerides; SBP = systolic blood pressure. 
Pearson’s and Spearman’s correlation coefficients for normally and not normally distributed 
variables, significant correlations (p<0.05) are marked in bold. Not normally distributed variables: A-
SAA, alcohol intake, triglycerides, fasting insulin, HbA1c, 2h-glucose, and hs-CRP. 
 
 
Table 2 Appendix. Association between circulating concentrations of A-SAA and incident 
T2DM adjusted for age, sex and different measures of obesity and body composition 
  A-SAA 
Covariables OR (95% CI) P 
age + sex + BMI (n=836) 1.25 [1.05-1.50] 0.01 
age + sex + WHR (n=836) 1.26 [1.05-1.51] 0.01 
age + sex + fat mass index (n=832) 1.26 [1.05-1.51] 0.01 
age + sex + lean body mass index (n=832) 1.30 [1.08-1.56] 0.005 
age + sex + appendicular skeletal muscle mass index (n=832) 1.31 [1.09-1.57] 0.005 
 
Odds ratios (95% CI) are given for a 1-SD increase of A-SAA concentrations (4.16mg/l). Fat mass 
index, lean body mass index and appendicular skeletal muscle mass index have been calculated in 
kg/m² as proposed by Kyle [204, 205].  
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Table 3 Appendix. Association between elevated levels of A-SAA and incident type 2 diabetes 
adjusted for age, sex and, alternatively, menopausal status, hormone replacement therapy, liver 
disease and the intake of aspirin 
  A-SAA 
Covariates OR (95% CI) P 
age + sex + menopausal status (n=836) 1.28 [1.07-1.53] 0.006 
age + sex + HRT (n=835) 1.28 [1.08-1.53] 0.005 
age + sex + liver disease (n=836) 1.28 [1.08-1.53] 0.005 
age + sex + intake of aspirin (n=836) 1.28 [1.08-1.53] 0.006 
  
HRT=hormone replacement therapy  
Odds ratios (95% CI) are given for a 1-SD increase of A-SAA concentrations (4.16mg/l). Menopausal 
status is coded in eight categories (ovarectomy and hysterectomy, only ovarectomy, only 
hysterectomy, either ovarectomy or hysterectomy, and no information on the other variable, pre-
menopausal, post-menopausal, sound uterus and hormone therapy, and male). HRT is coded in three 
categories (yes, no, male). Liver disease within the last 12 months is coded in three categories (yes, 
no, no information). Intake of aspirin is coded in yes/no.  
 
 
Text 1 Appendix. Study descriptions  
KORA studies 
The Cooperative Health Research in the Region of Augsburg (KORA) study is a series of independent 
population-based epidemiological surveys and follow-up studies of participants living in the region of 
Augsburg, Southern Germany. All participants are residents of German nationality identified through 
the registration and informed consent has been given by all participants [230]. The study has been 
approved by the local ethics committee. The present study includes data of the KORA S4 survey 
(1999/2000), the follow-up study F4 (2006-2008) and the follow-up study of KORA S3 survey 
(1994/1995) F3 (2004/2005).  For the genome-wide association study we genotyped 1,814 randomly 
selected participants of KORA F4 with Affymetrix 6.0. A-SAA measurements were available for 
1,785 of these participants. Additionally, 27 SNPs, which were identified in the meta-analysis, were 
genotyped with the MassARRAY system using the iPLEX technology (Sequenom) in all participants 
with A-SAA measurements of the KORA S4 study (N=3,677) thus providing one sample for 
validation (N=2,136) and one sample for the comparison of the genotyping technologies (N=1,541, 
corresponding to the sample genotyped with Affymetrix 6.0). For the comparison of the genotyping 
technologies, we used an additional subsample of 717 KORA S4 participants with genotyping data 
available from the Illumina 550K platform. Correlation analysis was conducted in all participants of 
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S4 (N=4,261) and F3 (N=3,006) where measurements of SAA, hs-CRP, fibrinogen and leptin were 
available. Methods for measurement have been described in detail elsewhere [148, 231].  
LURIC study 
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study includes consecutive white 
patients of Caucasian origin (17 to 92 years of age) hospitalized for coronary angiography between 
June 1997 and May 2001 [232]. The study was approved by the ethics review committee at the 
“Landesärztekammer Rheinland-Pfalz”. Written informed consent was obtained from each of the 
participants. Clinical indications for angiography were chest pain or non-invasive tests consistent with 
myocardial ischemia. To limit clinical heterogeneity, individuals suffering from acute illness other 
than acute coronary syndromes, chronic non-cardiac diseases and a history of malignancy within the 
five past years were excluded. The present study includes data of 1002 participants for whom 
Affymetrix 6.0 genotyping data was available. 
 
Sorbs study 
All subjects are part of a sample from an extensively phenotyped self-contained population from 
Eastern Germany, the Sorbs (PMID: 19584900; PMID: 19729412). The Sorbs are of Slavonic origin, 
and lived in ethnic isolation among the Germanic majority during the past 1100 years. At present, 
about 1000 Sorbian individuals are enrolled in the study. Sampling comprised unrelated subjects as 
well as families. Mean IBD sharing in the pairwise comparison was 0.008, median <10
-6
 (25% 
percentile <10
-6
, 75% percentile: 0.012). Extensive phenotyping included standardised questionnaires 
for past medical history and family history, collection of anthropometric data and a 75g-Glucose-
tolerance-test. The study was approved by the ethics committee of the University of Leipzig and all 
subjects gave written informed consent before taking part in the study. 
 
TwinsUK study 
The TwinsUK adult twin registry based at St Thomas’ Hospital in London is a volunteer cohort of 
over 10,000 twins recruited among the general population. Twins largely volunteered unaware of any 
their phenotypic status in relationship to SAA or any other phenotypic trait of interest to the authors 
and they gave fully informed consent under a protocol reviewed by the St Thomas’ Hospital Local 
Research Ethics Committee. All participants in the TwinsUK study were female and SAA 
measurements were obtained as described in the main Methods section. 
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Table 4 Appendix. Study characteristics of the four studies of the meta-analysis and the 
validation sample 
Study KORA S4 LURIC Sorbs TwinsUK 
validation 
sample 
N all 
(males/females) 
1785 
(874/911) 
961 
(693/268) 
883 
(361/522) 
583 
(0/583) 
2136 
(1069/1067) 
Age mean [years](sd) 
53.91  
(8.87) 
64.14 
(10.80) 
47.89 
(16.31) 
56.74 
(10.39) 
45.66  
(15.76) 
BMI mean [kg/m²](sd) 
27.72  
(4.55) 
26.53  
(4.52) 
27.05  
(4.94) 
24.67 (4.03) 
26.87  
(4.75) 
SAA geometric mean 
[mg/L] 
3.35 6.61 3.09 5.61 3.10 
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Table 5 Appendix. Study specific information on genotyping and imputation 
study KORA S4 LURIC Sorbs TwinsUK 
genotyping  
platform 
Affymetrix 6.0 Affymetrix 6.0 
Affymetrix 500K 
Affymetrix 6.0 
Illumina 317k 
Illumina 610k 
calling 
algorithm 
Birdseed Birdseed 
BRLMM 
Birdseed 
Illuminus 
QC filters  
before  
imputation 
individual 
callrate 
≥ 0.93 ≥ 0.96 none ≥ 0.95 
SNP 
callrate 
none none ≥ 0.95 ≥ 0.95 
HWE none none < 0.0001 < 0.0001 
MAF none none > 0.01 > 0.01 
imputation 
software 
IMPUTE v0.4.2 IMPUTE v0.4.2  IMPUTE v1.0.0 IMPUTE v1.0.0 
number of SNPs in 
meta-analysis 
2,498,895 2,515,584 2,363,460 2,416,789 
inflation factor  0.999 1.025 1.184 1.136 
statistical software SNPTEST  
v2.1.0 
SNPTEST 
v2.1.0 
QUICKTEST 
v0.95 
Merlin 
v1.1.2 
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Table 6 Appendix. List of all significantly associated SNPs of the meta-analysis 
 
SNP chr pos effect allele other allele ß se(ß) p      n        I² 
rs4150642 11 18327474 G C 0.5012 0.0224 3.20E-111 4179 70.25 
rs7103375 11 18332109 G A 0.5012 0.0224 3.26E-111 4179 70.25 
rs4638289 11 18242350 A T 0.3045 0.0198 2.77E-53 4143 76.45 
rs4353250 11 18280093 T C 0.2719 0.0180 1.68E-51 4206 67.88 
rs2061164 11 18285582 T C 0.2722 0.0180 1.92E-51 4206 67.53 
rs10741739 11 18284260 G T 0.2719 0.0180 2.27E-51 4210 68.05 
rs3825025 11 18300398 C G 0.2711 0.0180 5.32E-51 4210 68.49 
rs4150550 11 18307474 C G 0.2704 0.0180 9.77E-51 4210 68.34 
rs4150561 11 18311453 T C 0.2697 0.0180 1.54E-50 4210 68.18 
rs4150562 11 18311571 A G 0.2697 0.0180 1.58E-50 4210 68.16 
rs4150564 11 18311884 G A 0.2696 0.0180 1.66E-50 4210 68.13 
rs4150616 11 18321690 A T 0.2695 0.0180 1.79E-50 4210 68.02 
rs4150641 11 18327315 C A 0.2695 0.0180 1.79E-50 4210 68.02 
rs4150650 11 18330855 G A 0.2695 0.0180 1.79E-50 4210 68.02 
rs4150651 11 18331001 T C 0.2695 0.0180 1.79E-50 4210 68.02 
rs4150661 11 18336205 C A 0.2694 0.0180 1.80E-50 4210 68.01 
rs3740711 11 18336415 T C 0.2694 0.0180 1.81E-50 4210 68.01 
rs4150612 11 18320934 G T 0.2695 0.0180 1.82E-50 4210 68.02 
rs4150610 11 18320716 A G 0.2694 0.0180 1.83E-50 4210 68.01 
rs4150575 11 18313042 C T 0.2693 0.0180 2.06E-50 4210 67.99 
rs9783347 11 18341514 A G 0.2692 0.0180 2.08E-50 4210 67.98 
rs9988866 11 18349559 T A 0.2673 0.0180 3.68E-50 4210 68.38 
rs10741741 11 18298657 T C 0.2648 0.0179 1.96E-49 4197 63.24 
rs1520884 11 18266276 A G 0.2687 0.0182 3.03E-49 4166 67.39 
rs1993373 11 18237211 A G 0.2860 0.0194 4.21E-49 4206 84.34 
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rs4150615 11 18321604 C T 0.2642 0.0180 8.49E-49 4208 65.86 
rs7950019 11 18235488 G A 0.2857 0.0195 1.40E-48 4211 85.10 
rs7112278 11 18238492 C T 0.2828 0.0193 2.09E-48 4157 81.62 
rs4150655 11 18331740 A T 0.2669 0.0185 3.99E-47 4083 67.37 
rs4150622 11 18322286 A G 0.2626 0.0183 8.67E-47 4187 69.91 
rs4757638 11 18269529 G A 0.2619 0.0183 1.12E-46 4127 62.08 
rs4150579 11 18313756 A G 0.2598 0.0182 2.63E-46 4185 67.39 
rs4150673 11 18340025 T G 0.2528 0.0180 1.26E-44 4191 66.21 
rs11024614 11 18283334 C T 0.2338 0.0172 5.05E-42 4205 59.09 
rs4150628 11 18322444 G A 0.2314 0.0172 3.44E-41 4210 58.74 
rs4150606 11 18320145 C A 0.2314 0.0172 3.54E-41 4210 58.73 
rs4757645 11 18350421 C G 0.2284 0.0179 3.26E-37 4092 64.16 
rs11024613 11 18283118 T C 0.2159 0.0172 3.74E-36 4178 55.69 
rs3802967 11 18300640 T C 0.2173 0.0173 5.18E-36 4181 61.73 
rs2403254 11 18281722 C T 0.2150 0.0172 6.07E-36 4168 54.32 
rs10832920 11 18298445 A G 0.2154 0.0172 6.35E-36 4183 55.67 
rs4757637 11 18264151 C A 0.2231 0.0180 2.10E-35 4177 72.63 
rs4596 11 18344704 G C 0.2138 0.0172 2.17E-35 4182 58.32 
rs2037867 11 18338597 A G 0.2137 0.0172 2.17E-35 4182 57.92 
rs2305564 11 18274034 T A 0.2114 0.0173 3.76E-34 4152 60.63 
rs4150581 11 18313846 A G 0.2027 0.0173 7.68E-32 4160 50.29 
rs10832918 11 18292260 G A 0.2437 0.0238 1.09E-24 2722* 0.00 
rs3781945 11 18262848 G A 0.1879 0.0194 3.89E-22 3874 78.09 
rs2896526 11 18376382 G A 0.2211 0.0229 4.12E-22 4211 60.51 
rs2271997 11 18259980 C T 0.1870 0.0211 8.67E-19 3213** 84.34 
rs4150563 11 18311678 T G 0.2284 0.0261 2.15E-18 4024 84.42 
rs12218 11 18247897 T C 0.1650 0.0189 2.18E-18 4104 76.82 
rs2045272 11 18234674 T G 0.1582 0.0188 4.46E-17 4210 55.78 
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rs2056781 11 18401565 A G 0.2191 0.0266 1.98E-16 4210 77.72 
rs16935424 11 18413313 T A 0.2191 0.0267 2.13E-16 4210 77.83 
rs16935432 11 18427063 A G 0.2192 0.0267 2.28E-16 4210 77.93 
rs12289603 11 18427946 C T 0.2193 0.0267 2.29E-16 4210 77.98 
rs4150667 11 18339487 C T 0.2011 0.0245 2.31E-16 4015 82.93 
rs3740713 11 18407672 C A 0.2118 0.0268 2.84E-15 4176 77.08 
rs7131332 11 18252099 A G 0.1493 0.0189 3.22E-15 4115 39.79 
rs11024600 11 18252386 T C 0.1468 0.0189 8.22E-15 4210 49.84 
rs11024603 11 18262975 G A 0.1543 0.0215 8.05E-13 4143 43.30 
rs35593189 11 18424954 A G 0.2379 0.0344 4.66E-12 2725* 33.34 
rs12291480 11 18262333 G C 0.1446 0.0231 3.57E-10 4107 34.21 
rs1046615 11 18257530 G A 0.1343 0.0226 2.95E-09 3244** 17.62 
rs12416821 11 18257705 A G 0.1341 0.0226 3.07E-09 3244** 18.03 
rs12419588 11 18257706 G A 0.1341 0.0226 3.07E-09 3244** 18.03 
rs2049129 11 18261909 T C 0.1340 0.0235 1.12E-08 4026 21.75 
rs12753193 1 65942267 A G 0.1248 0.0184 1.22E-11 4212 0.00 
rs7541434 1 65941087 C A 0.1243 0.0184 1.35E-11 4202 0.00 
rs7524581 1 65939087 C T 0.1217 0.0183 2.82E-11 4206 0.00 
rs2211651 1 65928609 G T 0.1132 0.0177 1.66E-10 4210 0.00 
rs1805096 1 65874845 G A 0.1127 0.0177 1.92E-10 4207 0.00 
rs6588158 1 65933209 C T 0.1135 0.0178 1.99E-10 4211 0.00 
rs4420065 1 65934049 C T 0.1133 0.0179 2.23E-10 4212 0.00 
rs4655584 1 65928103 T G 0.1123 0.0177 2.29E-10 4211 0.00 
rs4655585 1 65928215 T C 0.1123 0.0177 2.30E-10 4211 0.00 
rs1938492 1 65890417 A C 0.1122 0.0177 2.33E-10 4210 0.00 
rs2889195 1 65929318 C T 0.1123 0.0178 3.00E-10 4181 0.00 
rs11208711 1 65920434 G T 0.1114 0.0177 3.12E-10 4210 0.00 
rs4655582 1 65925951 C G 0.1114 0.0177 3.20E-10 4211 0.00 
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rs10789192 1 65898358 G A 0.1113 0.0177 3.27E-10 4211 0.00 
rs12042779 1 65906538 T C 0.1110 0.0177 3.65E-10 4210 0.00 
rs12042807 1 65906640 T C 0.1110 0.0177 3.65E-10 4210 0.00 
rs7516341 1 65860731 T C 0.1125 0.0180 4.27E-10 4181 18.00 
rs7531867 1 65880134 G A 0.1107 0.0178 4.44E-10 4187 0.00 
rs10889569 1 65858782 A T 0.1122 0.0180 4.71E-10 4183 20.80 
rs6588153 1 65864605 T A 0.1181 0.0190 4.87E-10 4089 0.00 
rs6700896 1 65862370 C T 0.1116 0.0180 5.93E-10 4177 4.96 
rs6678033 1 65850212 G A 0.1097 0.0180 1.21E-09 4178 27.85 
rs1892534 1 65878532 C T 0.1074 0.0177 1.33E-09 4206 0.00 
rs4655794 1 65931889 T C 0.1018 0.0174 5.29E-09 4210 0.00 
rs12022410 1 65926521 A G 0.1001 0.0174 9.51E-09 4211 0.00 
rs4655783 1 65915632 T C 0.1000 0.0174 9.57E-09 4208 0.00 
rs11208700 1 65906031 A T 0.0999 0.0174 9.84E-09 4208 0.00 
rs10789198 1 65975343 G A 0.0991 0.0174 1.20E-08 4183 0.00 
rs10889576 1 65941154 C T 0.1256 0.0221 1.31E-08 4197 0.00 
rs4288572 1 65973610 G A 0.0988 0.0174 1.33E-08 4184 0.00 
rs11208728 1 65985631 A G 0.0985 0.0174 1.48E-08 4182 0.00 
rs4655800 1 65984279 A G 0.0991 0.0175 1.54E-08 4167 0.00 
rs6696954 1 65827583 T G 0.1057 0.0187 1.56E-08 4192 0.00 
rs17407727 1 65944594 A C 0.1038 0.0184 1.80E-08 4197 50.67 
rs4425959 1 65940407 A G 0.1242 0.0221 2.02E-08 4194 0.00 
rs17416194 1 65943780 A G 0.1035 0.0186 2.50E-08 4164 48.62 
rs4278348 1 65947983 T C 0.0947 0.0172 3.54E-08 4209 34.48 
rs7532805 1 65955718 G A 0.0939 0.0172 4.64E-08 4208 35.69 
 
* only KORA S4 and LURIC,  ** only KORA S4, LURIC, and TwinsUK 
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Table 7 Appendix. Genotypic mean levels 
  Geometric means (sd) of A-SAA levels 
KORA LURIC Sorbs TwinsUK 
 Validation 
sample 
rs4150642 
11p15.5-p14 
locus 
GG 7.296 
(2.367) 
13.052 (3.939) 5.815 (2.114) 7.657 (0.256) 5.933 (2.395) 
GC 4.450 
(2.207) 
9.573 (3.891) 4.279 (2.036) 7.787 (2.790) 4.192 (2.294) 
CC 2.769 
(2.080) 
5.151 (3.455) 2.488 (2.061) 5.111(0.471) 2.518 (2.255) 
rs4638289 
SAA1 
subregion 
AA 4.730 
(2.383) 
7.594 (3.676) 4.398 (2.182) 7.306 (0.618) 4.469 (2.333) 
AT 3.739 
(2.188) 
7.599 (3.843) 3.507 (2.073) 6.196 (0.599) 3.371 (2.349) 
TT 2.688 
(2.107) 
5.430 (3.623) 2.393 (2.112) 5.018 (2.240) 2.511 (2.303) 
rs4353250 
HPS5/ 
GTF2H1 
subregion 
TT 5.091 
(2.492) 
9.969 (3.837) 4.532 (2.361) 7.511 (2.740) 4.805 (2.674) 
TC 3.534 
(2.190) 
7.843 (3.762) 3.259 (2.102) 5.989 (2.447) 3.456 (2.254) 
CC 2.845 
(2.103) 
4.914 (3.517) 2.385 (1.981) 5.178 (0.477) 2.463 (2.264) 
rs2896526 
LDHA/LDHC 
subregion 
GG 4.788 
(2.051) 
12.469 (4.545) 4.455 (2.383) 6.660 (2.581) 4.227 (2.566) 
GA 4.005 
(2.400) 
7.793 (3.835) 3.642 (2.142) 6.123 (2.474) 3.607 (2.441) 
AA 3.050 
(2.126) 
5.974 (3.656) 2.867 (2.146) 5.393 (0.488) 2.861 (2.327) 
rs12753193 
1p31 locus 
(LEPR) 
AA 3.673 
(2.209) 
7.120 (3.710) 3.484 (2.269) 6.221 (2.494) 3.410 (2.468) 
AG 3.241 
(2.234) 
6.570 (3.758) 2.981 (2.112) 5.398 (0.508) 2.983 (2.342) 
GG 2.961 
(2.223) 
5.725 (3.888) 2.614 (2.023) 4.742 (0.364) 2.789 ( 2.240) 
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rs549485 
11p14 locus 
(SERGEF) 
(males only) 
TT 3.779 
(2.595) 
8.583 (4.342) 3.320 (2.925) NA 3.148 
(2.419)* 
TC 3.132 
(2.202) 
6.119 (3.810) 3.072 (2.103) NA 2.723 
(2.217)* 
CC 2.728 
(2.202) 
6.093 (4.117) 2.239 (2.200) NA 2.611 
(2.455)* 
 
* For technical reasons rs549485 was replaced by rs493767 (r²=0.961, 3rd lowest p-value within this 
region in the gender stratified meta-analysis) in the validation analysis 
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Table 8 Appendix. Comparison between different genotyping technologies in the KORA study 
Region SNP 
Genotyping 
technology 
 
Effect 
allele 
Other 
allele imp n beta se(beta) p 
 
11p15.5-p14 
locus 
rs4150642 
Affymetrix 
6.0 G C I 1785 0.529 0.032 
1.92E-
58 
Sequenom 
G C G 1494 0.470 0.032 
1.03E-
44 
rs7103375 
 
Affymetrix 
6.0 G A I 1785 0.529 0.032 
1.93E-
58 
Sequenom 
G A G 1538 0.473 0.032 
1.27E-
46 
Illumina 
550k G A G 707 0.522 0.050 
3.61E-
24 
 
SAA1 
subregion  
rs4638289 
 
Affymetrix 
6.0 A T I 1785 0.323 0.027 
4.95E-
31 
Sequenom 
A T G 1516 0.344 0.028 
1.46E-
32 
rs1993373 
 
Affymetrix 
6.0 A G I 1785 0.313 0.027 
2.07E-
29 
Sequenom 
A G G 1397 0.348 0.029 
1.06E-
30 
rs2045272 
 
Affymetrix 
6.0 T G I 1785 0.199 0.028 
2.33E-
12 
Sequenom 
T G G 1526 0.202 0.028 
2.12E-
12 
Illumina 
550k T G G 712 0.115 0.042 
5.79E-
03 
 
HPS5/ 
GTF2H1 
subregion 
rs4353250 
 
Affymetrix 
6.0 T C I 1785 0.278 0.027 
1.06E-
24 
Sequenom 
T C G 1534 0.274 0.029 
3.23E-
21 
rs9988866 
Affymetrix 
T A G 1785 0.270 0.027 
9.24E-
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6.0 24 
Sequenom 
T A G 1534 0.275 0.028 
1.26E-
21 
rs1520884 
Affymetrix 
6.0 A G G 1780 0.271 0.027 
1.00E-
23 
Sequenom 
T C G 1459 0.250 0.028 
3.24E-
19 
rs4150655 
Affymetrix 
6.0 A T G 1659 0.272 0.028 
4.51E-
21 
Sequenom 
A T G 1530 0.266 0.029 
5.18E-
20 
rs4757637 
Affymetrix 
6.0 C A G 1751 0.213 0.026 
4.56E-
16 
Sequenom 
C A G 1526 0.232 0.028 
6.93E-
17 
Illumina 
550k C A G 705 0.176 0.041 
2.19E-
05 
rs4150581 
Affymetrix 
6.0 A G G 1768 0.203 0.026 
8.18E-
15 
Sequenom 
A G G 1499 0.210 0.028 
3.93E-
14 
Illumina 
550k A G G 714 0.191 0.040 
1.79E-
06 
rs11024603 
 
Affymetrix 
6.0 G A G 1782 0.188 0.032 
5.76E-
09 
Sequenom 
G A G 1540 0.181 0.035 
1.90E-
07 
 
Illumina 
550k G A G 715 0.204 0.051 
6.26E-
05 
 
LDHA/LDHC 
subregion 
rs2896526 
 
Affymetrix 
6.0 G A I 1785 0.265 0.033 
3.99E-
15 
Sequenom 
G A G 1511 0.252 0.035 
1.46E-
12 
Illumina G A G 716 0.304 0.053 
1.15E-
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550k 08 
rs12289603 
 
Affymetrix 
6.0 A G I 1785 0.269 0.039 
5.81E-
12 
Sequenom 
T C G 1390 0.212 0.038 
1.95E-
08 
rs12289603 
Affymetrix 
6.0 C T I 1785 0.269 0.039 
6.15E-
12 
Sequenom 
C T G 1535 0.260 0.040 
8.56E-
11 
rs3740713 
Affymetrix 
6.0 C A G 1749 0.257 0.039 
8.35E-
11 
Sequenom 
G T G 1532 0.237 0.041 
6.32E-
09 
Illumina 
550k G T G 702 0.274 0.061 
7.54E-
06 
rs35593189 
Affymetrix 
6.0 A G G 1764 0.255 0.037 
1.07E-
11 
 Sequenom 
A G G 1526 0.255 0.040 
2.66E-
10 
 
1p31 locus 
(LEPR) 
rs12753193 
Affymetrix 
6.0 A G I 1785 0.103 0.027 
1.94E-
04 
Sequenom 
A G G 1536 0.062 0.029 
3.10E-
02 
Illumina 
550k A G G 715 0.117 0.043 
6.02E-
03 
rs7524581 
 
Affymetrix 
6.0 C T I 1785 0.101 0.027 
2.45E-
04 
Sequenom 
C T G 1534 0.053 0.029 
6.67E-
02 
Illumina 
550k C T G 715 0.107 0.043 
1.20E-
02 
rs2211651 
Affymetrix 
6.0 G T I 1785 0.093 0.026 
4.17E-
04 
Sequenom G T G 1499 0.071 0.029 
1.53E-
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02 
Illumina 
550k G T G 715 0.113 0.043 
8.17E-
03 
rs2889195 
 
Affymetrix 
6.0 C T G 1754 0.092 0.027 
5.90E-
04 
Sequenom 
C T G 1519 0.066 0.029 
2.16E-
02 
Illumina 
550k C T G 716 0.113 0.043 
7.76E-
03 
rs1892534 
 
 
Affymetrix 
6.0 C T G 1779 0.092 0.026 
5.27E-
04 
Sequenom 
G A G 1511 0.069 0.028 
1.42E-
02 
Illumina 
550k G A G 716 0.104 0.043 
1.45E-
02 
rs12022410 
 
Affymetrix 
6.0 A G I 1785 0.093 0.027 
5.66E-
04 
Sequenom 
A G G 1498 0.026 0.029 
3.79E-
01 
Illumina 
550k A G G 715 0.097 0.041 
1.84E-
02 
 
rs17407727 
 
Affymetrix 
6.0 A C G 1773 0.106 0.028 
1.45E-
04 
 Sequenom 
A C G 1509 0.075 0.030 
1.29E-
02 
 
Illumina 
550k A C G 716 0.129 0.045 
3.75E-
03 
 
rs17416194 
Affymetrix 
6.0 A G G 1744 0.105 0.028 
2.04E-
04 
 Sequenom 
A G G 1491 0.076 0.030 
1.17E-
02 
 
Illumina 
550k A G G 716 0.124 0.045 
5.60E-
03 
11p14 locus rs493767 Affymetrix C G G 860 0.140 0.040 
5.66E-
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(SERGEF) 
(males only) 
6.0 04 
Sequenom C G G 
749 0.142 0.041 
5.75E-
04 
rs550659  
Affymetrix 
6.0 
G A G 
873 0.131 0.040 
1.16E-
03 
Sequenom G A G 
742 0.143 0.041 
5.97E-
04 
 
 
 
 
Table 9 Appendix. Analysis of the structure of the chromosome 11 region 
    Single SNP model Multiple SNP model 
rs4150642 beta 0.501       
11p15.5-p13 se 0.022       
  p 3.20E-111 ∆R² = 0.1084*     
rs4638289 beta 0.305   0.254*   
SAA1 subregion se 0.020   0.024*   
  p 2.77E-53 ∆R² = 0.0557* 7.61E-27*   
rs4353250 beta 0.272   0.212*   
HPS5/GTF2H1 subregion se 0.018   0.022*   
  p 1.68E-51 ∆R² = 0.0534* 3.64E-22*   
rs2896526 beta 0.221   0.106*   
LDHA/LDHC subregion se 0.023   0.025*   
  p 4.12E-22 ∆R² = 0.0237* 1.81E-05* ∆R² = 0.0910* 
      
* Values calculated for KORA S4, LURIC, and the Sorbs.  
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Table 10 Appendix. Results of the validation analyses  
Region SNP 
Effect 
allele 
Other 
allele 
Effect 
allele 
freq n beta se(beta) p 
11p15.5-p14 
locus 
rs4150642 G C 0.217 2082 0.473 0.029 7.41E-58 
rs7103375 G A 0.215 2130 0.460 0.028 2.27E-56 
 
SAA1 subregion  
rs4638289 A T 0.332 2091 0.292 0.025 1.61E-30 
rs1993373 A G 0.327 1939 0.297 0.026 2.04E-29 
rs2045272 T G 0.581 2118 0.207 0.024 4.09E-17 
 
HPS5/ GTF2H1 subregion 
rs4353250 T C 0.352 2125 0.345 0.025 5.82E-42 
rs9988866 T A 0.359 2125 0.355 0.025 6.62E-45 
rs1520884 T C 0.356 2034 0.318 0.024 9.14E-38 
rs4150655 A T 0.323 2123 0.343 0.025 1.52E-41 
rs4757637 C A 0.406 2109 0.286 0.025 1.48E-29 
rs4150581 A G 0.486 2072 0.250 0.024 9.31E-25 
 rs11024603 G A 0.828 2127 0.058 0.031 5.74E-02 
 
 
LDHA/LDHC subregion 
rs2896526 G A 0.187 2097 0.216 0.031 8.18E-12 
rs2056781 T C 0.170 1942 0.157 0.032 1.17E-06 
rs12289603 C T 0.120 2131 0.219 0.034 1.69E-10 
rs3740713 G T 0.109 2117 0.188 0.036 1.67E-07 
rs35593189 A G 0.116 2113 0.213 0.035 1.11E-09 
 
 
1p31 locus 
(LEPR) 
rs12753193 A G 0.606 2127 0.085 0.025 8.60E-04 
rs7524581 C T 0.624 2123 0.080 0.026 1.85E-03 
rs2211651 G T 0.591 2079 0.069 0.025 6.89E-03 
rs2889195 C T 0.603 2116 0.075 0.025 2.94E-03 
rs1892534 G A 0.627 2090 0.070 0.025 5.39E-03 
rs12022410 A G 0.410 2089 0.072 0.026 5.32E-03 
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rs17407727 A C 0.288 2085 0.067 0.027 1.55E-02 
 rs17416194 A G 0.278 2063 0.055 0.027 4.20E-02 
11p14 locus 
(SERGEF)males 
rs493767 C G 0.349 1049 0.091 0.035 8.50E-03 
rs550659  G A 0.373 1041 0.084 0.035 1.65E-02 
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A-SAA  acute-phase serum amyloid A 
ADA  American Diabetes Association  
BMI  body mass index 
C-SAA  constitutive serum amyloid A 
C/EBP  CCAAT/enhancer binding protein 
CI  confidence interval 
DGDG  Diabetes Gene Discovery Group 
DGI  Diabetes Genetics Initiative 
DIAGRAM Diabetes Genetics Replication and Meta-analysis Consortium 
EUROSPAN European Special Population Network 
FFA   free-fatty acids 
FUSION Finland-United States Investigation of Non-Insulin Dependent Diabetes Genetics 
GCSF  granulocyte colony-stimulating factor 
GTF2H1  general transcription factor 2 H1 
GWAS  genome-wide association study 
HapMap Haplotype Mapping  
HbA1c  hemoglobin A1c 
HDL  high-density lipoprotein  
HOMA-IR homeostasis model assessment for insulin resistance 
HPS5  Hermansky-Pudlak Syndrome 5 
hs-CRP  high sensitivity-C reactive protein 
HWE  Hard-Weinberg equilibrium   
ICAM-1 intercellular adhesion molecule-1 
IDF  International Diabetes Federation 
IFG  impaired fasting glucose 
IGT  impaired glucose tolerance 
IκK   inhibitor of NF-κ B kinase  
IL (-1, -1ß, -6, -8, -18) interleukin (-1, -1ß, -6, -8, -18) 
IL-1Ra  interleukin 1 receptor antagonist 
iNOS   inducible nitric oxide synthase 
IRS (-1, -2) insulin receptor substrate (-1, -2) 
JNK   JunkN terminal kinase 
KCNC1 potassium voltage-gated channel subfamily C member 1  
KCNJ11 potassium inwardly-rectifying channel, subfamily J, member 11 
KORA  Cooperative Research in the Region of Augsburg 
7. Guide to abbreviations 
VI 
 
LADA  late-onset autoimmunity diabetes in the adult 
LD  linkage disequilibrium 
LDHA   lactate dehydrogenase A  
LDHC   lactate dehydrogenase C 
LEPR  leptin receptor 
LIF  leukemia inhibitory factor 
LURIC  Ludwigshafen Risk and Cardiovascular Health study 
MAF  Minor allele frequency 
MAGIC Meta-Analyses of Glucose and Insulin-related traits Consortium 
MCP-1  monocyte chemotactic protein-1 
MODY  maturity-onset diabetes in the young 
MONICA  Monitoring of Trends and Determinants in Cardiovascular Disease 
MYOD1  myogenic differentiation 1 
NF-κB  nuclear factor κB 
NO  nitric oxide 
OGTT  oral glucose tolerance test 
OR  odds ratio 
PAI-1  plasminogen activator inhibitor-1 
PKC (-θ ) protein kinase C (-θ) 
ROS  reactive oxidative species 
PPAR (α, γ) peroxisome proliferator-activated receptor (α, γ)  
SAA  serum amyloid A 
SERGEF secretion regulating guanine nucleotide exchange factor 
SNP  single nucleotide polymorphism 
SOCS (-3) suppressor of cytokine signaling (-3) 
TCF7L2 transcription factor 7-like 2 
TNF-α  tumor necrosis factor-α 
TPH  tryptophan hydroxylase 
TWINS UK adult twin register 
WHO  World Health Organization 
WHR  waist-to-hip ratio 
WTCCC/  Welcome Trust Case Control Consortium/ 
   UKT2D    United Kingdom Type 2 Diabetes Genetics Consortium 
YY1  ying and yang 1 
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